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ABSTRACT

THE DEVELOPMENT OF HYBRID PROCESS CONTROL SYSTEMS
FOR FLUIDIZED BED PELLET COATING PROCESSES

By
Hanzhou Feng
May 2019

Dissertation supervised by Carl A. Anderson, Ph.D.
The conventional basic control for pharmaceutical batch processes has several
drawbacks. The basic control often uses constant process settings discovered by trial and
error. The rigid process operation provides limited process understanding and forgoes the
opportunities of process optimization. Product quality attributes are measured by the low
efficient off-line tests, therefore these cannot be used to monitor and inform the process to
make appropriate adjustments. Frequent reprocessing and batch failures are possible
consequences if the process is not under effective control. These issues raise serious
concerns of the process capability of a pharmaceutical manufacturing process.
An alternative process control strategy is perceived as a logical way to improve the
process capability. To demonstrate the strategy, a hybrid control system is proposed in this
work. A challenging aqueous drug layering process, which had a batch failure rate of 30%
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when operated using basic control, was investigated as a model system to develop and
demonstrate the hybrid control system.
The hybrid control consisted of process manipulation, monitoring and optimization.
First principle control was developed to manipulate the process. It used a theory of
environmental equivalency to regulate a consistent drying rate for the drug layering process.
The process manipulation method successfully eliminated the batch failures previously
encountered in the basic control approach. Process monitoring was achieved by building
an empirical analytical model using in-line Near-Infrared spectroscopy. The model allowed
real time quantitative analysis of drug layered content and was able to determine the
endpoint of the process. It achieved quality assurance without relying on the end product
tests. Process optimization was accomplished by discovering optimum process settings in
an operation space. The operation space was constructed using edge of failure analysis on
a design space. It provided setpoints with higher confidence to meet the specifications. The
integration of the control elements enabled a complete hybrid control system. The results
showed the process capability of the drug layering process was significantly improved by
using the hybrid control. The effectiveness was substantiated by statistical evidence of the
process capability indices.
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Chapter 1: Introduction
1.1 Statement of the Problem
Pharmaceutical manufacturing is a critical part of an effective health care system. Although
in the past ten years the industry has witnessed a significant development in continuous processes,
to date the manufacturing is still highly dependent on batch processing. Due to its advantages such
as better adaptability and cost efficiency, batch process is widely used for production of solid drug
products (Wold et al.).
Efficient process control engineering and practice have now matured and are extensively
employed in fluid-based petroleum and chemical industries (Benyahia et al., 2012). In these
applications, the process dynamics are often driven by chemical reactions, which have response
times measured in minutes to hours. In a solid-phase pharmaceutical unit operation, the physical
changes usually occur within seconds or minutes (Su et al., 2017). This requires much faster
response of the control system. Therefore, the process control experience may not be directly
transferable to support the more challenging pharmaceutical processing.
The pharmaceutical industry is under one of the most strict regulations. Pharmaceutical
products must be produced to meet the desired specifications by manufacturing procedures strictly
controlled at desirable process conditions submitted to the regulatory. Any changes made during
this process will lead to re-evaluation by the regulatory agency, therefore the pharmaceutical
batches were usually produced at constant settings and operated under the conventional basic
control. The process operation relies on tightly constrained material attributes and process
parameters, which are discovered mostly by trial and errors (Abe et al., 1998). Because at-/in-line
analyzer results are often unavailable, the process endpoint often determined based on operator’s
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experience. The processed materials must be tested off-line, and thus the results of the quality test
cannot be used in a real time manner to inform the process operation. The variability of quality is
trapped in the batch endpoint, potentially producing more substandard products.
Process capability is often used to describe the ability of a process to manufacture quality
products that meet the required specifications (Ziemer, 1993) According to the opinions from the
pharmaceutical industry (Shanley, 2017), little change has been made to improve the process
capability in the past ten years. Using a Six Sigma quality management criterion, the
pharmaceutical industry to date still remains at two to three sigma quality levels, whereas five
sigma is a general standard practice for industries such as automotive, electronics, etc. The sigma
level can be converted to defects rate as shown in Table 1.1. In general, the defect rate of a
pharmaceutical process is approximately more than 300 times larger than most other industries.
Table 1. 1 Six Sigma criterion.

Defects per million
opportunities (PPM)
691462
308538
66807
6210
233
3

Sigma level

1
2
3
4
5
6

Cpk

0.333
0.667
1.000
1.333
1.667
2.000

Conforming
level %
68.27
95.45
99.73
99.9936
99.99994
99.9999998

Capability rating

Terrible
Poor
Marginally capable
Capable
Good
Excellent

The quality deficiency is evidenced by the number of drug recalls. According to FDA’s
data (Gaffney, 2014), the two years of 2013-2014 reported 2061 drug recalls. While the sheer
numbers are troubling enough, what is more concerning is the reasons of the recalls. The
overwhelming majority of the recalls is driven by Class I (21%) and Class II recalls (70 percent).
Based on the classifications of drug recalls (FDA, 2010), the data indicates most of the recalls
2

were issued due to serious adverse health effects. In total, about 30% of the recalls was caused by
failing to meet the prescribed specifications. From the perspectives of consumers and regulators,
pharmaceutical companies should provide reliable access to safe, efficacious, stable and affordable
high quality pharmaceutical products. Unfortunately, the expectations have not been met.
Although the shortcomings discussed above reflect poor quality practices in the
pharmaceutical industry, it also implies there are many opportunities for improvement.
Recognizing the need to improve product quality, FDA encouraged the manufacturers to employ
the latest scientific advances in pharmaceutical manufacturing and technology. In the guidelines
put forth by the International Conference on Harmonization (FDA, 2004a), the desired
pharmaceutical manufacturing should include effective and efficient process operations,
appropriate product specifications based on process understanding, and continuous real time
quality assurance provided by process monitoring. The advancement of new technology and
updated regulatory policy has offered opportunities to develop alternative control strategy. The
ICH Q8 (R2) guideline introduced the “quality-by-design (QbD)” concept and allow for operation
flexibility within a validated design space (FDA, 2009). In the QbD approach, there is no rigid
restriction of constant process settings. The use of design of experiments (DOE) with supported
prior knowledge is valuable to enhance process understanding. The application of process
analytical technology (PAT) allows developing process monitoring system to provide real time
quality measurements. These advancements have provided necessary basis and tools to achieve a
desired pharmaceutical manufacturing.
The goal of this dissertation was to develop an alternative control strategy for a
pharmaceutical manufacturing using batch process. Considering the unique position of the coating
process in a series of consecutive unit operations, it is critical to have an effective control to prevent
3

batch failures and ensure product quality. Therefore, this dissertation considered fluidized bed
pellet coating as a suitable model system for demonstrating the development of an alternative
control strategy.
Fluidized bed processing is a well-known challenging unit operation. Although the
equipment and process parameters influencing the quality of finished products are identified in
literature (Banks, 1981), the process itself is known to be multivariate and complex by nature.
There are several problems associated with the fluidized bed coating process. The most serious
one is the high risk of batch collapse due to agglomeration (Lipsanen et al., 2008). Uneven and
lumpy agglomerates are easily produced during the random movement of the coated particles.
Depending on the drying capacity and liquid viscosity, the growth of agglomerates may lead to
wet-quenching or dry-quenching, causing drastic and instant batch collapse (Dewettinck et al.,
1998). The fluidized bed pellet coating process is usually operated using basic control. Fixed
process settings discovered in trial and errors are used under the supervision of the operator.
Nevertheless, a fixed process condition does not always guarantee successful coating batch
production for long-term manufacturing. The dissertation proposes to develop a hybrid control
system to improve the process capability of a fluidized bed pellet coating process. The hybrid
control system consists of three parts: process manipulation, monitoring, and optimization. The
drug product quality is expected to benefit from the successful development of the proposed
control strategy.

4

1.2 Hypothesis and Specific Aims
The dissertation is based on the central hypothesis that a hybrid process control system,
developed by integrating first principle control, empirical analytical models, and operation space,
can improve the process capability of a fluidized bed pellet coating process.
Given the central hypothesis, the specific aims of this dissertation were to:
(1)

Establish a process manipulation method, based on first principle control, to improve the

process operation and reduce batch failure.
(2)

Build empirical analytical models to allow real time process monitoring of critical quality

attributes (CQA).
(3)

Construct an operation space, predicated on the concept of design space and edge of failure,

to enable process optimization.
(4)

Compare the process capability obtained using the hybrid control with the basic control.

(5)

Explore the possibility of a broader applications using the hybrid control system.

1.3 Literature Survey
1.3.1 Fluidized Bed Coating
1.3.1.1 Flow Regimes and Solid Particles for Fluidization
Fluidized bed equipment has become an integral part of the pharmaceutical industry for
implementing and improving drying, granulating, and many types of coating and layering
operations. As the technology of fluidized bed batch processing equipment has evolved, attention
has turned to the sophisticated issues of safety, adherence to CGMPs, product-handling systems,
quality control and process automation. A sufficient understanding of the interdependence between
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the processes and the specific design requirements is essential if high quality and effective products
are to be produced in a safe and efficient environment (Olsen, 1989a).
A fluidized bed is a packed bed through which fluid flows at such a high velocity that the
particle bed is loosened and the particle-fluid mixture behaves as though it is a fluid. Thus, when
a bed of particles is fluidized, the entire bed can be transported like a fluid, if desired. Both gas
and liquid flows can be used to fluidize a bed of particles. The most common reason for fluidizing
a bed is to obtain vigorous agitation of the solids in contact with the fluid (Yang, 2003). Therefore,
this process is commonly used for several purposes, such as fluidized bed reactors, solid separation,
fluid catalytic cracking, and coating on solid items (Yang, 2003).
In the pharmaceutical industry, fluidized bed processing is often utilized for coating small
particles or pellets. Inside the bed, solid particles are suspended in a fluid-like state using gas
introduced from the bottom of the bed. The gas is normally preheated before it is pumped to the
bed where it acts as both heat and momentum carrier. In the coating process, a layer is deposited
onto the surface of fluidized solid particles by spraying with a solution or suspension of the coating
material. The goals are usually to load drug or modify the properties of the particles (Cole, 2002).
Different regimes of fluidizations are displayed in Figure 1.1. The dilute phase flow
characterized by the fast fluidization and suspension flow. It is commonly used for pneumatic
conveying systems, and might only occur as a by-pass process for emptying the fluidized bed
column (Rabinovich and Kalman, 2011). For a wide particle size distribution, the large particles
are fluidized at the lower part of the column, while the fine powders might be carried over by a
dilute flow regime (Kalman and Rabinovich, 2008). By reducing the gas velocity, the suspension
flow is halted and particle clusters might appear. Yerushalmi referred to the flow regime occurring
after the appearances of particle clusters as fast fluidization (Yerushalmi and Cankurt, 1979). In
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addition, the literature presents the main characteristics of the turbulent fluidization, slugging,
bubbling and fluidized flow regimes. The turbulent fluidization regime is characterized by extreme
particle turbulence without large discrete bubbles or voids. The slugging flow regime is
characterized by a particle dense phase transport that is facilitated by bubbles whose size is
comparable to the pipe diameter size. The bubbling flow regime can be similarly characterized,
however, the bubbles are much smaller. The fluidized flow regime is characterized by particle
dense phase fluidization or transport without bubbles (Rabinovich and Kalman, 2011). The plug
flow regimes are not common in fluidized bed system, they may occur in pneumatic conveying
system.

Figure 1. 1 Permission granted and reproduced from Rabinovich and Kalman. Schematics of flow regimes for vertical
pneumatic conveying and fluidized bed systems.

Geldart’s classification of particles is a good guidance in deciding the suitability of seed
particle for fluidized bed coating (Geldart, 1973) . Geldart plotted a powder classification diagram
using experimental data, from a wide variety of researchers who have commented on the behavior
of the powders with which they worked. The plot of particle density vs. mean size is shown in
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Figure 1.2. The fully open symbols represent powders which the authors remarked were extremely
difficult to fluidize (group C), the half-closed symbols represent powders where bubble free bed
expansion were noted (group A), and the solid symbols where they were specifically mentioned
that bed expansion was low and/or bubbling occurred at or very close to minimum fluidization
velocity. Geldart commented the justification of group D is not readily apparent as there is
relatively little published information is available (Geldart, 1973).
The Geldart C particles have a particle size range below 30 µm. The strong inter-particulate
forces greatly affect the fluidization behavior, normal fluidization of such powders is extremely
difficult. The powder lifts as a plug or channels as shown in Figure 1.2. The difficulty arises
because the inter-particulate forces are greater than those which the fluid can exert on the particle,
and these are generally the result of very small particle size, strong electrostatic charges or the
presence in the bed of very wet or sticky material. Poor particle mixing and heat transfer would be
expected, therefore fluidized bed is inadequate for processing the class C particles.
Other types of particles are easier for fluidized bed processing. Geldart A materials have a
small mean size and/or a low particle density (less than about 1.4 g/cm 3). Beds of this group expand
considerably before bubbling commences. Gross circulation of the particles (akin to convection
currents in liquids) easily produce rapid mixing even when few bubbles are present. Bubbles in a
two-dimensional bed appear to split and recoalesce very frequently. Group B contains most
materials in the mean size and density ranges 40 – 500 µm, and 1.4 – 4 g/cm 3. In contrast with
group A powders, naturally occurring bubbles start to form at or only slightly above minimum
fluidization velocity. There is little or no powder circulation in the absence of bubbles, and bubbles
burst at the surface of the bed as discrete entities. When the air velocity increases, bubbles
coalescence leads to slugging commences. Group D powders were confined to large and/or very
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dense particles. The solids mixing relatively poor, the flow regime around particles in this group
may be turbulent, causing some particle attrition with rapid elutriation of the fines produced
(Geldart, 1973).

Figure 1. 2 Permission granted and reproduced from Geldart. Power classification diagram for fluidization by air.

1.3.1.2 Classifications of Fluidized Bed Systems
The classification of fluidized bed process is easily characterized by the nozzle position.
Three configurations are commonly involved in pharmaceutical manufacturing: top-spray, bottomspray, and tangential-spray with rotating risk (Wen and Park, 2010). The top-spray system has
been successfully used to coat materials as small as 100 μm (Dewettinck et al., 1998). A typical
top-spray configuration is shown in Figure 1.3 (A). The product container is an unbaffled, inverted
and truncated cone. Inlet air stream is drawn through the air distributor, entered the product
container from the bottom. The resulting particle motion is unrestricted and presumed random.
The nozzle is positioned above the powder bed, from which atomized coating liquid is sprayed
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downward onto the fluidized particles. In this system, controlling the distance that droplets travel
before impacting on the particles is very difficult due to the vigorous and random fluidization
behavior. Consequently, premature droplet evaporation can be quite severe, and as a result coating
imperfections may occur. The higher the degree of drying, the more viscous the droplets get before
impinging on the particle substrate, resulting in a degradation of the coating solution’s filmforming properties (Cole, 2002). The spray dried fine coating material is collected by the filter
housing at the top of the fluidized bed, and should be considered a loss (Dewettinck et al., 1998).
The coating layer produced by a top-spray system always involves imperfections to a certain extent
(Ronsse, 2006), this method is less suited for controlled release products, and is nowadays
primarily used for barrier (protective) coatings.
The bottom-spray system is also known as the Wurster system. Originally designed to coat
pharmaceutical tablets, it is now widely used for processing substrates as small as 50 μm (Turton
and Cheng, 2005). The coating chamber contains an unbaffled, open-ended cylinder known as the
partition, as shown in Figure 1.3 (B). The size of the gap between the partition and the air
distributor is adjustable. The aim of the partition is to create ordered particle movement. Compared
to the top-spray configuration, the bottom-spray configuration produces coating films which are
more uniform and have a superior quality (less imperfections), and thus bottom-spray is better
suited to produce controlled release encapsulated products. In a bottom-spray coating process, the
particle motion, the number of passages and the time spent during each passage through the
spraying region, is well controlled as opposed to the top-spray configuration, where particles
motion is presumably random and uncontrolled. Furthermore, droplets are deposited concurrently,
assuring minimum droplet travel distance. Due to the extremely short droplet travel distance,
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premature droplet evaporation is almost absent. The film-forming droplets can spread out at the
lowest viscosity, producing a very dense film with a superior physical quality (Lan et al., 2011).
The third, and most recently developed fluidized bed system is the tangential-spray (Figure
1.3 (C)) (Bouffard et al., 2007). Instead of using an air distributor, a solid, rotating disc is installed
at the base of the reactor. A narrow gap exists between the reactor wall and the rotating disc,
through which the process air is drawn. The particle motion resulting from the combination of the
lift force created by the upward flowing process air, gravity, and the friction force created by the
rotating disc, could best be described as a spiraling helix. Beneath the surface of the rapidly
tumbling bed, one or more nozzles are positioned to spray the coating liquid tangentially to and
concurrently with the flow of particles. As a result of short droplet travel distances (concurrent
spray) and the rapid tumbling of the particle bed, high quality coating films are obtained which are
comparable to those produced by the Wurster process.

Figure 1. 3 Permission granted and reproduced from Wen and Park. Schematic drawing of top-spray/bottomspray/rotary-spray system.
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Wurster system is generally acknowledged more suitable for particle coating (Cole, 2002).
However, it has several shortcomings (Olsen, 1989a). The poor adaptability of Wurster system
requires many design considerations when materials of different particle sizes are processed. For
example, for tablet coating the system should be cylindrical. The percentage of open area in the
orifice plate should be adjustable because the ratio of airflow through the center partition to the
airflow outside the partition will need to be adjusted according to tablet size, shape and density.
The partition height above the orifice plate needs to be adjustable for the same reason. When the
system is used to coat smaller particles, the expansion space above the partition should be increased
to allow greater expansion of the fluidized bed. Furthermore, the shape of the expansion chamber
should be changed from cylindrical to conical to provide a deceleration zone for the particles. Also,
the height of the partition should be adjustable as it may be necessary to adjust the height during
operation considering the large amount of coating is applied. The adjustment of the partition height
depends on the particle size, amount of materials, bulk density, and the properties of coating
materials. In some cases, a specially designed partition might be required for coating small
powders. The scale-up of batch size is particularly difficult for Wurster system, as the number of
inner partitions increases as does the diameter of the cylindrical outer wall. The complex design
change requires many adjustments of the process parameters and configurations (Olsen, 1989a).
The top-spray fluidized bed has advantages such as high versatility, relative simplicity, and
higher batch size. There is much less adjustment required on the equipment design for different
materials. It is easy for batch to batch manufacturing. A simple replacement of the nozzles would
make the system ready for next batch. Top-spray system also allows larger batch size, especially
considering the industrial scale (could be up to 2200 L) compared to Wurster system
(approximately 600 L) (Olsen, 1989a). The challenges of using top-spray system are mainly
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resulted from the lack of controlled fluidization. It is more difficult to control the travel of coating
droplets. However, the risk of wet quenching of the top-spray system is much lower than bottom
spray system. The danger posed by wet quenching sometimes will favor the use of top-spraying
despite the bottom-spray is ideally more suited for coating.

1.3.1.3 Functions of Coating
A film coating is a thin polymer-based coat applied to a solid dosage form such as a tablet,
granule or pellet. The thickness of such a coating is usually between 20 and 100 µm (Cole, 2002).
Depending on the purposes, there are two types of coating: conventional and functional. The term
conventional film coating has been used to describe coatings applied for reasons of improved
product appearance, improved handling, and prevention of dusting, etc (Rowe, 1985; Sakellariou
and Rowe, 1995). Although conventional coating offers no particular therapeutic advantages, it
has considerable psychological importance in aiding patient compliance in taking the medicine.
Functional coating has been used to achieve several purposes. It can be used for drug
loading, where a different drug is applied to a non-functional or drug-loaded substrate such as
tablet or particles (Avalle et al., 2014; Chevalier et al., 2010; Ho et al., 2009a; Lilja et al., 2013;
Wang et al., 2012), to achieve combined drug administration. Sometimes, the same drug is applied
with suitable polymers to add an immediate release layer (Li et al., 2010), in order to achieve a
specific drug administration requirement. Many drugs formulated in tablet or particles are light or
moisture sensitive (Bley et al., 2009; Tønnesen, 2001). Opacifiers, e.g., titanium dioxide or
pigments with high refractive indices, are often included in film coatings to decrease the rate and
amount of light degradation. Coating materials with low inherent water vapor permeability is often
employed to reduce the ingress of moisture. Film coatings are effective in modifying the drug
release regulated by drug diffusion (Ozturk et al., 1990), polymer erosion (Cao et al., 2005), and
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osmosis (Herrlich et al., 2012). For diffusion-controlled release, the core is coated with a water
insoluble copolymers (e.g., ethyl cellulose or methacrylate ester) alone or in combination with a
water soluble ingredient (e.g., Hydroxlpropyl Methylcellulose (HPMC)) such that the film
permeability can be modified. For release determined by polymer erosion, the core is coated with
either a sparing soluble or pH dependent soluble film (e.g., cellulose acetate phthalate) such that
the drug release will be dictated by the dissolution of the polymer. For osmosis-controlled release,
a small orifice is drilled through the semipermeable coating film. The drug release is determined
by the permeability of the film and the core formulation (Sakellariou and Rowe, 1995).

1.3.1.4 Physical Phenomena in Fluidized Bed Coating
There are numerous possible processes can take place inside the bed, depending on the
process conditions, particle characteristics, and coating materials used. Figure 1.4 summarizes the
possible physical phenomena during fluidized bed coating, based on possible mechanisms
suggested by literature (Maronga, 1998).
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Figure 1. 4 Physical phenomena during fluidized bed coating.

Spray dried fine particles result from premature evaporation of the atomized droplets, if
they are unable to reach the particle surface and stay attached by adhesion. The fines may be
elutriated out or remain in the bed, depending on the weight and density (Saleh et al., 1999). The
fine powders that remain in the bed can be joined with other spray-dried fines, resulting in fineagglomeration, or they can be captured by larger particles causing ‘snow ball’ growth. When an
atomized coating liquid successfully impinge on particles, it wets their surfaces. Depending on the
conditions inside the bed, wetted particles may collide and form liquid bridges between themselves,
or can be dried resulting in a layered growth. If there is excessive wetting, many particles will join
together to form large wet clumps, inducing de-fluidization of the bed in a phenomenon known as
wet quenching. In the case of moderately wetted particles, a number of solid particles will remain
joined together when their liquid bridges are dried. The continuing existence of these solid bridges
depends on their strength. If the adhesive force is strong and the solid bridges join together many
particles, then these particles will remain joined and the bed will eventually collapse as it can not
fluidize these large particles. This phenomenon is also known as dry quenching. At the same time,
if the adhesive force is strong but the solid bridges joins together only a few particles, the process
will continue and the resulting product will be a few particles joined together to form larger
particles, i.e., agglomeration. On the other hand, if the adhesive forces are weak, the dried solid
bridges will break, leaving some coating on the surface of the particles. This will eventually lead
to coated particles. The challenge in achieving a successful coating process is to ensure that the
sprayed coating material reaches the particles, without causing excessive wetting. This has to be
done inside the bed in the presence of all three phases as time heat, mass and momentum transfers
are taking place at the same time.
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1.3.1.5 Effects of Process Parameters
The fluidizing gas velocity is a parameter which influences both the operation stability and
coating parameters. The hydrodynamic behavior of the fluidized bed coater is strongly dependent
on the fluidizing gas velocity. An adequate choice of this parameter is essential to avoid batch
collapse, unplanned agglomeration, and to keep stable operation for long periods.
In general, the lower the gas velocity, the faster the de-fluidization of the bed takes place.
The behavior can be qualitatively explained using the Ennis’ model of cohesive forces of mobile
liquid bridges (Ennis et al., 1991). According to Ennis, in the case of a fluidized bed the transition
to the inertial regime will occur when the particles have reached a sufficient size such that the
largest collision velocity will cause particle rebound and prevent agglomeration. Note that this
corresponds to the maximum size of agglomerates which can be formed at a given velocity in the
bed. The critical size at which the transition takes place depends on the humidity content and
relative velocity of particles, which is given by Eq. (1.1),

𝑑 =

[

(

)

(

)

Eq. (1.1)

ln( )]

In this equation, the humidity content and relative velocity are represented through h and U B/DB
(bubble velocity and bubble size). According to Davidson and Harison’s relationship (Davidson
and Harrison, 1963) to estimate the bubble velocity and Mori and Wen’s correlation (Mori and
Wen, 1975) for bubble diameter, the term UB/DB increases linearly with fluidizing air velocity.
Therefore, by reducing of the fluidizing air velocity, a decrease in relative velocity and increase of
humidity content lead to higher values of dp. Under these conditions dp would exceed the initial
diameter of the particles, and all collisions between particles are successful. Under this condition,
the growth is governed by agglomeration.
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The atomization conditions influence the mechanism and quality of deposition by
modifying the size of liquid droplets (Dewettinck et al., 1999). The change in droplet size affects
the coating growth rate and operation efficiency due to the two competitive phenomena of collision:
impingement of liquid on solid particles, and attrition (Guignon et al., 2003). Generally it is
accepted that the mean droplet size decreases by increasing atomizing pressure. Saleh et al. studied
the influences of atomization air flow rate and liquid flow rate on the droplet size. A sharp decrease
in the mean droplet size (from 60 to 20 µm) was observed when the atomizing air flow rate increase
four folds from 6.4 × 10

to 30.6 × 10

kg/s. The trend was reasonably modeled by

Nukiyama-Tanasawa correlation (Nukiyama and Tanasawa, 1938). The impingement efficiency
is expected to be increased when a higher atomization pressure is used, because of forming larger
number of droplets with greater velocity. However, a possible contradictive effect is that the
greater specific surface area of the smaller droplets enhances the chances of premature evaporation
and decreasing the impingement efficiency. The mean droplet size formed by the pneumatic spray
system did not vary significantly with the liquid flow rate (Saleh et al., 1999). This allowed the
droplet size to be controlled independently of the liquid spray rate (Olsen, 1989a, b).
Saleh et al. found the operation efficiency improved with the decrease in solid
concentration in the coating liquid (Saleh et al., 1999). Decreasing solid concentration often leads
to greater liquid viscosity, inhibiting the tendency of liquid premature evaporation. However, the
increased viscosity also strengthens the liquid adhesion to the particle surface, and forms stronger
liquid bridges. This, unfortunately, leads to a higher agglomeration rate. The initial particle weight,
or batch size, has not been reported having significant influence on coating growth rate, operation
efficiency, and agglomerate rate (Saleh et al., 1999), It can be taken as an indication that particle
wetting in a fluidized bed coater occurs only in a limited volume of bed called “atomization zone
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or spraying zone” (Smith, 1983), which is independent of the total mass of particles. The size of
this zone is determined by the penetration depth of the spray, which is a function of the gas velocity,
nozzle position, physical properties of the atomizing and fluidizing gas, and particle momentum.

1.3.2 Process Manipulation Approaches
In early fluidized bed coating studies, attempts have been made to monitor and control
critical process parameter with manual operation, i.e. basic control (Dewettinck and Huyghebaert,
1998; Lorck et al., 1997a; Maronga, 1998; Wesdyk et al., 1993). In the basic control approach, the
process is usually operated using constant process settings. Manual adjustments are often made to
compensate the batch to batch variation. A typical example is shown in Table 1.2 (Wesseling and
Bodmeier, 1999a), where three coating processes were produced using preset constant setpoints.
A well-known challenge associated with the fluidized bed processing is the process is susceptible
to the variation of ambient conditions. The inlet air temperature used for fluidized bed processing
is usually between 50-70 ˚C. At this low temperature range, the drying capacity is considerably
affected by the saturation humidity of the inlet air. This explains the observed wide range for each
parameter in Table 1.2, because the operator has to make adjustment for every batch based on the
specific environmental conditions. It is possible to enable automatic control using the basic control,
however, only feasible with the availability of an air-preconditioning system. The installment of
such system is very expensive, especially for large commercial scale facilities. More importantly,
they do not remove all variability. Large gradients with respect to temperature and humidity are
common within large manufacturing spaces, especially in the presence of a large work force
(Zacour, 2012).
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Table 1. 2 Permission granted and reproduced from Wesselin and Bodmeier. Process parameters for the
chlorpheniramine maleate layering and the coating of the drug-layered beads.

The first principle approach is established by quantifying the scientific mechanisms.
Because first principle control uses experimental data instead of statistical methods to estimate
model parameters, they are not as quick and easy to build, but have many advantages. By definition,
the calculations are based on material and environmental properties, so the calculations are
universal for all systems. Separate calibrations for new or adjusted formulations are unnecessary
(Zacour et al., 2012b). The calculations are also independent of equipment scale or type, meaning
first principle control is scalable and transferable. Property fluctuations or failure during
development can be explained using scientific principles, leading to easier interpretation and
greater process understanding. Complex interactions between processing parameters can be
accounted for by simply understanding their impact on simpler first principle mechanisms.
First principle control offers substantial economic advantage. The coating process
conditions discovered under basic control may not guarantee long-term success. The nature of the
coating process is extremely susceptible to many sources of variability, which may directly or
obliquely impact final product properties. Strictly controlling all sources of variability requires
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extraordinary capital investment. Nevertheless, such expenses could be unnecessary if the
investment into a rigorous first principle control system is made.
First principle control has been developed and applied to control fluidized bed drying and
tablet coating, with several approaches such as thermodynamic environment controls (Ende and
Berchielli, 2005; Reiland et al., 1983; Ronsse, 2006; Strong, 2009), residence time distribution
(Plawsky et al., 2010; Rodríguez-Rojo et al., 2008), population balance (Paulo Filho et al., 2006),
computational fluid dynamics (Hilton et al., 2013; Nunes et al., 2012; Šibanc et al., 2013), and
transport phenomena (Yang, 2003). Among them, Ebey’s work on developing thermodynamics
model (Ebey, 1987) is often referred to in the discussion of most relevant first principle approaches
for controlling coating process. The control proposes to stabilize the coating environment by
regulating the thermodynamic environment at a macroscopic-scale, based on the first principle
understanding of the heat-transfer and mass-transfer. An environmental equivalency factor (EEF)
is calculated by combining the original process parameters to a single value, which is used to
describe an overall drying rate for the process. By such variable reduction, the amount of
development and experimentation can be reduced exponentially.(Zacour et al., 2012a)
However, there are several shortcomings of the first principle control (Zacour, 2012). The
EEF calculation does not account for the detailed momentum transfer into its calculation. For
example, the atomization pressure is treated as a nuisance variable and held constant in the
calculation (Lecomte et al., 2003; Lee et al., 2011; Siepmann et al., 2008a). Nevertheless, it may
have significant influences on a coating process, because of its important roles affecting the
properties of the liquid droplet. Although the use of EEF provides a strategy for managing the
thermodynamic environment, additional understanding of its interaction with physical phenomena
at the microscopic level is helpful to achieve process optimization and effective control. Another
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shortcoming associated with the first principle control is the difficulty in quality assurance. The
measurements typically involved in a first principle control are temperature, humidity, etc. The
control does not directly measure the in-process materials, therefore provides no feedback to
determine the process endpoint. The product quality is still limited in a way similar to the basic
control.

1.3.3 Empirical Analytical Models based on Spectroscopic Techniques
Establishing an effective analytical method to determine the CQAs is a pivotal element in
the development of a control strategy. Unfortunately, the conventional analytical methods for
pharmaceutical products are often off-line and destructive laboratory tests, such as HPLC, in vitro
drug release, etc. Analytical approaches that are able to provide rapid and non-destructive
measurements of the CQAs are desirable to suit the augmented needs of continuous quality
assurance for developing effective process control (Yu and Kopcha, 2017).
The Food and Drug Administration (FDA) has encouraged the use of process analytical
technology (PAT) to support pharmaceutical development, manufacturing, and quality
assurance.(FDA, 2004a) In a PAT framework, process measurements are taken in three ways
(Figure 1.5) (FDA, 2004a). At-line: samples are removed from the process and analyzed in close
proximity to the process stream; on-line: samples are diverted from manufacturing process and
may be returned to the process stream after analyzing; in-line: samples are analyzed, in a real time
manner, without leaving a normal process. The distinction of modern PAT-based approach from a
conventional off-line is the time required for analysis. The time for manufacturing is insignificant
compared with the conventional off-line test, which has a broad range from minutes to several
days to obtain the results. Unlike the off-line test, PAT is able to offer real time quality
measurement that allows continuous process improvement.
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Figure 1. 5 Various ways of PAT measurements.

Near-Infrared (NIR) and Raman spectroscopy are two spectroscopic techniques most
commonly researched in the field of PAT. NIR spectroscopy is a vibrational spectroscopy, spans
the electromagnetic spectrum in the wavelength range of 780 – 2526 nm (Burns and Ciurczak,
2001). It provides information comes from overtones of molecular vibrations. Only vibrations
resulting in changes in dipole moment of a molecule can absorb NIR radiation. R-H functional
groups have the strongest overtones as the dipole moment is high, O-H, N-H, C-H, S-H bonds are
therefore strong absorbers. Because molecules differ in their vibrations, and hence in their
vibrational overtone spectra, the NIR region is valuable in characterizing chemical attributes
(Andersson et al., 1999). However, the overtones and combination bands often overlap, raising a
challenge in data interpretation (Burns and Ciurczak, 2001). A distinct spectra feature
characteristic of the analyte of interest is very hard to be obtained in NIR spectrum.
Raman is also a molecular vibrational spectroscopic technique. Unlike NIR, Raman
spectroscopy is highly selective. The basic principle in Raman spectroscopy is to irradiate a
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substance with monochromatic light and to detect the scattered light with a different frequency to
the incident beam. The differences in the frequencies between the incident and scattered radiation
result in characteristic Raman shifts (Rantanen, 2007). The Raman scattering refers to the inelastic
scattering of electromagnetic radiation as a result of energy exchange between the radiation and
molecular vibrations. It must be noted that the irradiation of materials can result in phenomena
other than scattering: e.g., absorption, and fluorescence (Wartewig and Neubert, 2005). Because
the Raman scattering is inherently weak, the other phenomena strongly interfere the desired signal.
The weak Raman signal is prone to various background effects, which complicates its quantitative
analysis (Bogomolov et al., 2010).
Although each has some limitations, the advantages offered by NIR and Raman
considerably outweigh their drawbacks. They are instantaneous, and non-destructive, requiring
minimal or no sample preparation (Muselík et al., 2010). Once calibrated, the methods are simple
to operate and suitable for determining the quality attributes of many types of samples. With the
availability of fiber probe modules coupled to the spectrometer, both techniques can be
implemented to the process streams, allowing continuous real time measurements. Therefore, NIR
and Raman have been increasingly used as an alternative analytical method to measure the quality
attributes of pharmaceutical products (Roggo et al., 2007; Wartewig and Neubert, 2005).
Several research groups have undertaken the application of NIR and Raman methods for
pharmaceutical coating analysis. Andersson was the first to attain the objective of real time
analysis of film coating using NIR in a Wurster fluidized bed (Andersson et al., 2000). A
subsequent study performed by Hudovornik revealed the comprehensive capability of using NIR
to achieve real time analysis of multiple coating characteristics (Hudovornik et al., 2015). After a
few attempts of applying Raman spectroscopy to characterize tablet coating properties (Kauffman
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et al., 2007; Romero-Torres et al., 2005). Bogomolov employed in-line Raman spectroscopy
combined with NIR to enable real time analysis of a fluidized bed pellet coating process
(Bogomolov et al., 2010). The literature has demonstrated NIR and Raman can provide means to
bypass time-consuming and expensive primary analytical methods. With appropriate modeling
method and performance assessment, the NIR and Raman models can provide predictions of the
CQAs with much reduced time and efforts. Therefore, the techniques find increasing acceptance
in the pharmaceutical industry as promising rapid surrogate tests for the analysis of raw materials
and final dosage forms (Kirsch and Drennen, 1995).
The in-line applications of NIR and Raman spectroscopy to monitor a pharmaceutical
manufacturing process generate a large amount of spectra data. Chemometric techniques are
required to explain the variation in the data and to extract useful process information leading to
process understanding and conclusions. Spectral pretreatment before chemometric analysis is
often desired to reduce the effect of interfering variance in which one is not interested, thereby
increasing the part of the variance due to parameters of interest. Although it is true that the
modeling process in multivariate calibration may accommodate for interferences and irrelevant
artefacts, careful data pretreatment often turns out to be more effective. General guidelines on how
to preprocess data are hard to give since this depends on the very specific application needed, such
as the nature of the samples and spectroscopic instrument (Vandeginste et al., 1998). Common
interfering factors include light scattering, path length variations, fluorescence, and random noise
resulting from variable physical sample properties or instrumental effects. Careful selection of data
pretreatments can significantly improve the model performance, the most commonly used methods
are standard normal variates (SNV).(Wu et al., 1995), Multiplicative Scatter Correction (MSC)
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(Geladi et al., 1985; Isaksson and Næs, 1988), first- or second-derivatives with Savitzky-Golay
filtering (Vandeginste et al., 1998).
Both NIR and Raman are secondary methods, meaning calibration is required to relate the
spectra signal to the reference method. Although the models can be developed with relatively
limited efforts, measurements of the CQAs by reference techniques are still required for calibration
model development. Under such circumstances, a technique that can offer efficient and direct
measurement of the CQAs, without the need of a calibration step, is extremely favorable. Terahertz
spectroscopy is a great candidate to meet the demands. The technique was not originally adopted
by pharmaceutical industry, until the development of modern terahertz spectrometers that take
advantage of novel semiconductor sources and detectors (Chan et al., 2007; Kindt and
Schmuttenmaer, 1996; Lu et al., 1998). Ultrafast femtosecond lasers and semiconductors are
employed to generate and detect short pulses of broadband terahertz radiation. The greater
radiation powers and higher detection sensitivity of semiconductor-based terahertz spectrometers
provide superior spectral results and performance (Schneider et al., 2006). The terahertz region of
the electromagnetic spectrum spans the frequency range between the mid-infrared and the
microwave.(Maurer and Leuenberger, 2009) The center portion of terahertz region is between 0.1
to 4 THz (wavelength from 0.075 to 3 mm). It primarily has been investigated for its ability to
characterize crystalline properties of solid materials (Ikeda et al., 2010; Strachan et al., 2004;
Taday, 2004), due to its absorption features dominated by collective phonon modes. Besides this
application, the low frequency radiation allows high penetration depth in solid samples, sometimes
can penetrate materials that are opaque to other spectral frequencies (Shen, 2011). The unique
transmission properties allow for non-invasive analysis and detection in various fields such as
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polymer manufacturing, material characterization and quality assurance in pharmaceutical
industry.
Terahertz hyperspectral imaging (THI) finds its particular importance in characterizing
pharmaceutical coating quality in the recent few years (Brock et al., 2012; Fitzgerald et al., 2005;
Haaser et al., 2013a; Haaser et al., 2013b; Ho et al., 2008, 2009b; Ho et al., 2007; Maurer and
Leuenberger, 2009; Shen, 2011). Many pharmaceutical coating materials are transparent or
semitransparent to the terahertz pulse. Because the macroscopic structure in the coating is much
less than the radiation wavelength, the insignificant scattering effect allows the terahertz wave to
penetrate deeper in solid samples. At each interface with a change in refractive indices, a portion
of the terahertz wave is reflected to the detector, generating a time-domain terahertz spectrum.
Compared to a reference signal with specular mirror reflectance, the time delay of the measured
signal was due to the traveling of terahertz wave through samples and between instrumental optics
and electronics. According to the fundamental mechanism of thickness measurement, Terahertz
method has been perceived as a direct method that provides non-destructive and rapid coating
thickness measurement (Knop and Kleinebudde, 2013).

1.3.4 Design Space, Edge of Failure, and Process Capability
Quality by Design (QbD) principles have been introduced to the pharmaceutical industry
by the FDA, and their implementation has been the object of specific guidelines by the ICH. QbD
has been defined as “a systematic approach to development that begins with predefined objectives
and emphasizes product and process understanding and process control based on sound science
and quality risk management”. Information from pharmaceutical development studies is a basis
for quality risk management. It introduces the concept that quality of pharmaceutical products
cannot be tested, instead it should be built in by design.
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The concept of design space has gained prominence as an effective tool for
implementation of QbD. It is defined as a multidimensional combination and interaction of input
variables (e.g., material attributes and process parameters) that have been demonstrated to provide
assurance of quality (FDA, 2009). A pharmaceutical design space is generally considered to be
the area where process parameters can be safely executed to achieve all CQAs and associated
product specifications. The establishment of design space is supported by the additional knowledge
gained by the changes in formulation and manufacturing processes during development and lifecycle management. Working within the design space is not considered as a change. Movement out
of the design space is considered to be a change and would normally initiate a regulatory postapproval change process.
The development of design space for pharmaceutical development has been reported in
several works (Fahmy et al., 2012; Kristan and Horvat, 2012; Zacour et al., 2012b). Although the
design space was initially conceptualized in context of pharmaceutical product quality, it has
expanded the utility to serve understanding the relations of process, product quality, analytical
methods, and even clinical properties (Bhatia et al., 2016; Furlanetto et al., 2013; Kristan and
Horvat, 2012).
Various analyses, including statistical modeling based on multifactorial design of
experiment (DOE), setpoint and optimization studies, are used to establish a design space (Little,
2014). Sometimes, however, design space alone is misleading because it represents an average of
the extrapolation of the response surface. The mean response may be safe, but the individual
batches may experience high failure rates. Therefore, a reliable design space requires supporting
analysis to assure regulatory the setpoints within the design space will have high success rates.
Edge of failure and process capability analysis are needed (Little, 2014). Edge of failure is an
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important addition to the design space, and defined as the point in the design space where
individual batches will fail the specifications. Although the regulatory does not consider the edge
of failure as a necessary element of establishing a design space , it is helpful to obtain a certain
level of confidence that applied to the entire design space .(FDA, 2009) Edge of failure can be
determined experimentally by exploring the design space until failures are found, or by simulating
the extrapolated design space even though failures were not experimentally detected. The first
way is extraordinarily expensive and time consuming and not required by the health authorities.
The second way is much more practical and a simple extension of the design optimization and
setpoint selection. The discovered edge of failure is often used to determine the design margin and
evaluate process capability.
Process capability is a measure of the ability of the process to produce product that meets
all CQAs and acceptance criteria. The concept of process capability can also be defined in
statistical terms. Capability indices have been developed to mathematically illustrate the
measurement of process capability. Statistical measurements of 𝐶 and 𝐶

are often used to

determine whether the process, given its natural variation, is capable of meeting established
specifications. They are calculated by,
Eq. 1.2

𝐶 =

𝐶

= min(

,

Eq. 1.3

)

where 𝑈𝑆𝐿 and 𝐿𝑆𝐿 are desired upper and lower specification limits of the investigated CQAs, 𝜇
and 𝑠 are the mean and standard deviation measured in experiments. 𝐶 measures how close a
process is running to its specification limits, relative to the natural variability of the process. The
larger the index, the less likely it is that any product will be outside the specifications. 𝐶
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is an

adjustment of 𝐶 for the effect of non-centered distribution. 𝐶

measures how close the products

of a process to its target, and how consistent the products are to their average performance. A high
𝐶 does not necessarily implies a high 𝐶

because the average of the product quality may be

towards one of the specification limits. Figure 1.6 graphically portrays the difference. Figure 1.6
(A) shows the effect of process variability on the capability indices. The two processes having
their own 𝐶 equals to 𝐶 , because the averages of the productions (the distribution of a quality
attribute) match the center target of the specifications. However, the 𝐶
is smaller than process B (𝐶

,

and 𝐶

,

,

and 𝐶

,

of process A

) because of its greater variation. The effect of deviation

from the center target is shown in Figure 1.6 (B). Process C has the same variation as Process A,
but its average is closer to USL, causing a lower 𝐶
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.

Figure 1. 6 Illustration of process capability indices. A: Effect of the variation of the distribution; B: Effect of the
deviation from the center limit.

1.4 Summary
Well-developed controls of pharmaceutical manufacturing are necessary to ensure product
quality. The dissertation aims to improve the process capability for pharmaceutical batch
processing using alternative control strategy. The challenges of controlling the fluidized bed
coating process discussed in this chapter made it an appropriate model system to demonstrate the
development of the control strategy. This work proposed a hybrid control system for the fluidized
bed coating process as a demonstration of developing an alternative control strategy. The hybrid
control system consists of three elements, process manipulation, monitoring, and optimization.
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Process manipulation method can be established using first principle control approach. The
theory of EEF is hypothesized to reduce the susceptibility of a pellet coating process to the
variation in ambient humidity by maintaining a consistent drying environment. Empirical
analytical models enable real time process monitoring of the CQAs, which allow unbiased and
consistent process adjustment and endpoint determination. Process optimization is achievable via
the development of operation space, which is expected to increase the confidence of meeting the
desired specifications. The completion of the hybrid control system is expected to improve the
process capability for the investigated fluidized bed pellet coating process.
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Chapter 2: Establish Process Manipulation Method based on First
Principle Control
2.1 Introduction
An effective method to manipulate a process is a prerequisite for developing any process
control system. Regardless of what type of control is employed, a mechanism to change the process
trajectory is required for successful operation. Therefore, establishing a valid process manipulation
method is the very first and crucial step for developing a desirable process control strategy.
Control of the coating process requires careful manipulation of the process parameters.
Coating, in general, is a challenging process suffering from high risk of batch failures. A failure in
coating typically causes the loss of the entire batch. Because coating is often used towards the end
of a solid product manufacturing, a batch failure entails the waste of all processed materials and
cumulative capital investment. There are many failure modes for the coating process: the most
serious problem in pellet coating is agglomeration.
In a coating process, wetting and drying are key physical phenomena (Maronga, 1998).
Wetting begins with the droplets of coating liquid impinge on the substrate. Drying evaporates the
solvent and leaves the solid content of the droplets on the surface. An excessive drying rate
produces fines and leads to elutriation. On the other hand, an insufficient drying rate enhances the
chances of forming agglomerates (Maa et al., 1996). The strong liquid and/or solid bridges formed
between pellets make it extremely difficult, if not impossible, to break and bring them back to
individual pellets. Under certain circumstances, the agglomerates grow rapidly and lead to defluidization and batch collapse.
Manual process operation, referred to as basic control in this work, is the conventional
approach to manipulate the pellet coating process. When basic control is used, acceptable process
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conditions are usually found through trial and error and are often held constant for future batch
production. Desirable coating results can be achieved by operating the process in a suitable drying
environment. However, it is not always easy to consistently maintain the process within the range
of a desired drying environment, because the drying capacity is often susceptible to the variation
in ambient humidity.
A rational way to control the pellet coating is to set conditions that minimize the risk of
forming agglomerates. This requires the process to be operated under appropriate conditions. The
work in this chapter proposes to develop a process manipulation strategy based on first principle
control. The purpose was to provide a steady drying environment that is less susceptible to the
variation of ambient humidity, thereby improving the process robustness and reducing pellet
coating batch failure.
An environmental equivalency factor (EEF) (Ebey, 1987), premised on simultaneous heat
and mass transfers (Crank, 1975), was used to develop the first principle control. During a drying
process, the inlet air supplies energy for the solvent vaporization via heat convection. The driving
force of the heat transfer is the temperature difference between the inlet air and the pellet. The
vaporized solvent is transported to the air stream via mass convection. The difference in vapor
partial pressure determines the mass transfer rate. The EEF theory considers the thermodynamic
environment of the process is unchanged as long as the same relationship is maintained between
the heat and mass transfers.
Based on the first principle understanding of the physical phenomena, an EEF is calculated
by consolidating process parameters relevant to the heat and mass transfers to a single value. The
EEF is used to indicate and regulate a drying environment. This work is predicated on the
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hypothesis that an adequate drying environment deduced from the validated process settings of
basic control, consistently controlled by EEF, produces desirable and reproducible coating result.
Near-Infrared (NIR) spectroscopy provides information that comes from overtones of
molecular vibrations. Because molecules differ in their vibrations, and hence in their vibrational
overtone spectra, the NIR region is valuable in characterizing chemical attributes (Andersson et
al., 1999). Historically, the first two quantitative NIR measurements were the determinations of
atmospheric moisture and water content in gelatin (Burns and Ciurczak, 2001). Owing to its high
sensitivity to water, a diffuse reflectance NIR spectroscopy was utilized to evaluate the effect of
the proposed method of controlling the drying environment.
The goals of this study were to (1) determine acceptable pellet coating conditions for
calculating a proper EEF target, (2) develop control algorithms to achieve first principle control
and manipulate the process, and (3) examine the effectiveness of the process manipulation method
on reducing batch failures. A traditionally difficult aqueous drug layering process was studied as
a model process. An automation system was deployed to allow feedback process manipulation.

2.2 Materials and methods
2.2.1 Formulation of Drug Layered Pellets
Pellets (SUGLETS, Colorcon, West Point, PA), made of sucrose and starch, were used as
cores for fluidized bed coating. The pellets have a diameter range of 1000-1200 μm and were
coated with a drug suspension. The formulation of the drug suspension is listed in Table 2.1.
Polymer solution was prepared by dissolving the desired amount of hypromellose (HPMC,
PharmaCoat 606, Shin-Etsu, Japan) to deionized water added with plasticizer PEG 400. The
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estimated viscosity was about 60 mPa·s at room temperature.(ShinEtsu) The model drug
acetaminophen (APAP) was mixed with the polymer solution prepared ahead of time for 24 hours
before each experiment.
Table 2. 1 Formulation of the drug suspension.

Components
APAP
HPMC
PEG 400
Deionized water

Drug suspension
Concentration (w/w)
10.00%
6.00%
1.50%
82.50%

2.2.2. Fluidized Bed System and Spectroscopic Data Collection
Fluidized bed coating was performed using a Diosna Minilab (Dierks & Sohne GmbH,
Osnabruck, Germany) fitted with a 7 L insert. A schematic diagram of the fluidized bed system
with incorporated process measurements is illustrated in Figure 2.1. The filter house consisted of
four filter bags, which were cleared using a back pressure pulse every 60 s at 30 psi for all
experiments. The coating liquid was applied to the system by a peristaltic pump, and the atomized
droplets were formed by a two-phase pneumatic nozzle. The system contained an internal EGEElectronik series LN/LG air flow sensor (Spezial-Sensoren GmbH, Gettorf, Germany) to measure
volumetric airflow velocity in the inlet air pipe. An electrical heater adjacent to the air pipe was
used to heat the inlet air before entering the system. Three internal thermocouples measured
temperature of the heated air, product temperature, and outlet air. Two temperature/humidity
transmitters (series RHL, Dwyer Instruments, Inc., Michigan City, IN) were added to the system
to measure the temperature and humidity of the inlet and exhaust air. The process measurements
were made at a frequency of 0.1 Hz.
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NIR spectra were collected through the side port of the fluidized bed. A model NIR256L2.2T2 diffuse reflectance spectrometer (Control Development Inc., South Bend, IN) was used. It
was a 256-element photodiode array spectrometer with an extended InGaAs detector. The NIR
spectrum had a range of 1085-2229 nm. An external halogen light source (HL-2000, Control
Development Inc., South Bend, IN) was used with a reflectance fiber optic probe (Control
Development Inc., South Bend, IN). The integration time was experimentally determined before
each batch, by calibrating using a Teflon reference sample. The integration time for NIR
measurement was usually in a range of 13 – 17 ms, depending on the warm-up time of the light
source. NIR data collection frequency was set at 0.2 Hz with an average of 16 co-adds per spectrum.

Figure 2. 1 Fluidized bed system with process and spectral measurements.
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2.2.3 Automation System
In this study, two control systems were investigated. The control commands were executed
using a closed-loop automation. Figure 2.2 displays an overall structure of the system. The analog
signal generated by the fluidized bed was collected and sent to an open platform communication
system (OPC): DeltaV (V 9.7, Emerson, MO). The DeltaV system had hardware I/O modules (Mseries, Emerson, MO) supporting analog, discrete, thermocouple, resistance temperature detector
(RTD) inputs. SynTQ (V3.5, Optimal, UK) is a real time data management system where control
commands, process and analytical models are implemented (Figure 2.2 blue squares). It
communicated with DeltaV to access the data of the fluidized bed. All of the process measurements
(process parameters and spectra data) and model predictions are synchronized to a fixed cycle, so
that the measurements for a given cycle can be compared. The fluidized bed drug layering process
consisted of four phases, including preheating (phase 1), spraying (phase 2), drying (phase 3), and
cooling (phase 4). Detailed control commands and process models of each phase were written in
orchestration programs stored in SynTQ. The control commands determined the process trajectory,
while the process models provided process settings. Constant process settings were used to operate
the process when the basic control was used. On the other hand, when the first principle control
was in use, a different process model in the spraying phase (red dashed line) was executed. In this
case, an EEF value was calculated for each cycle, and used to change the process settings. The
details are discussed in section 2.2.5. At the end of each synchronization cycle, SynTQ set the new
process settings to the fluidized bed via DeltaV.
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Figure 2. 2 Structure of the automation system.

2.2.4 Basic Control
The process parameters of the fluidized bed system are listed in Table 2.2. Although all
process parameters are measurable, there is a distinction between manipulated parameters and
measured parameters. Manipulated parameters are adjustable, whereas measured parameters are
only measurable. The air flow velocity (AF), inlet air temperature (IT) and spray rate (SR) were
in automatic control, because their setpoints were changed using DeltaV. The atomization pressure
(AP) was not included in the automated system, and therefore had to be changed manually.
Appropriate process settings for each coating phase were experimentally determined by
accommodating two criteria: (1) successful operations for three consecutive batches, and (2) less
than 1% (w/w) agglomeration rate determined by sieve analysis (mesh opening of 2.38 mm). The
initial experiments for finding acceptable process condition were conducted at ambient relative
humidity (RH) range of 10-20%.
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Table 2. 2 Process parameters of the fluidized bed system.

Types of parameter
Manipulated
parameters

Measured
parameters

Names of parameter
Air flow velocity
Inlet air temperature
Spray rate
Atomization pressure
Product temperature
Ambient air temperature
Exhaust air temperature
Ambient air relative humidity
Exhaust air relative humidity

Types of control
Automatic control
Manual control

No direct control

2.2.5 First Principle Control
An EEF target value was required to establish the first principle control. Acceptable
process setpoints discovered in the basic control with associated process parameters were used in
the calculation of EEF. The equation used for the calculation is,

𝐸𝐸𝐹 =

(

)
(

Eq. (2.1)

)

Here 𝑀 is molar mass of water, 𝑅 is gas constant; 𝜌

and 𝐶𝑝 are the density and specific heat

capacity of the heated inlet air. 𝑃 is the partial vapor pressure of the inlet air, and 𝑃 represents
the partial vapor pressure near the wet surface of the pellets; 𝑇 and 𝑇 are wet-bulb temperature
and product temperature of the pellets; ℎ

is the specific enthalpy change of water evaporation.

The derivations can be found in Ebey’s original work (Ebey, 1987). The EEF target was
subsequently used to design a feedback control system, which is displayed in Figure 2.3. Two
control algorithms, univariate and Simplex, were designed and used as controllers for
implementing the first principle control approaches. The algorithms provided the fluidized bed
with control inputs, which were new setpoints for the manipulated parameters. A new EEF value
was calculated based on the updated process parameters using Eq. (2.1), and was compared with
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the EEF target to estimate the control error. The control error guided the algorithms to calculate
new setpoints for operating the fluidized bed. The EEF values were expected to be controlled at
the target by using an effective control algorithm.

Figure 2. 3 Feedback loop of the first principle control

2.2.5.1 Univariate Control Algorithm
Univariate control is a single variable control system with one input and one output (Koivo
and Tanttu, 1991). In the investigated system, the control input was one of the manipulated
parameters (AF, IT and SR), and the output was the EEF calculated during the process. The
manipulated parameters can be adjusted to control the process by comparing the EEF output with
the target value. Each manipulated parameter was confined to a predefined range, out of the
concern for equipment and operation safety. IT and AF were allowed to change in the ranges of
40-80 ˚C and 30-75 m3/h, respectively. The range of SR was set 4-15 g/min. The desired setpoint
of each manipulated parameter can be calculated by a transformed equation of Eq. (2.1). An
example of calculating the IT setpoint is by,
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(2.2)
In the equation above, all the terms on the right side are known, whereas the left side 𝑇 is the
unknown IT setpoint that needs to be solved. The calculated setpoint was updated at a frequency
of 0.1 Hz to manipulate the process.

2.2.5.2 Simplex Control Algorithm
Simplex control was developed by integrating the concept of Multi-Input Multi-Output
(MIMO) (Koivo and Tanttu, 1991) and design of experiment (DOE). In this system, all of the
three manipulated parameters were control inputs, and also treated as factors in a DOE. The DOE
was used to study the relations of the control inputs and identify the optimum setpoints of each
manipulated parameter. A Simplex-Lattice design was chosen for its efficiency to study the effects
of three factors at multiple levels (Giles et al., 2005). In the DOE, each manipulated parameter had
10 levels spanning their operable ranges. A combination of the setpoints of the manipulated
parameters was regarded as an experimental design point, which was illustrated by the blue dots
in Figure 2.4.
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Figure 2. 4 Simplex-Lattice design of experiments.

The combinations of the setpoints generated by the DOE are listed in Table 2.3. An EEF
value was calculated using each combination of the setpoints with other process parameters
measured during the process. All of the EEF values at each cycle were compared with the target
to calculate the control error. The combination of the setpoints producing the lowest control error
was identified as the optimum process settings and used to manipulate the process. The first
principle control using the Simplex-Lattice DOE is abbreviated as Simplex control in this
dissertation.
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Table 2. 3 Combinations of the setpoints generated by the Simplex-Lattice DOE

Design
AF
point (m3/h)
1
39.0
2
35.0
3
51.0
4
39.0
5
43.0
6
43.0
7
35.0
8
39.0
9
47.0
10
67.0
11
43.0
12
59.0
13
51.0
14
63.0
15
47.0
16
39.0
17
71.0
18
47.0
19
51.0
20
35.0
21
51.0
22
59.0
23
43.0
24
35.0
25
47.0
26
35.0
27
67.0
28
55.0
29
43.0
30
43.0
31
51.0
32
59.0
33
71.0

IT
SR
(˚C) (g/min)
72.0
5.1
60.0
9.5
64.0
4.0
48.0
11.7
56.0
8.4
52.0
9.5
64.0
8.4
76.0
4.0
60.0
6.2
48.0
4.0
72.0
4.0
52.0
5.1
40.0
10.6
40.0
7.3
64.0
5.1
52.0
10.6
40.0
5.1
48.0
9.5
44.0
9.5
40.0
15.0
56.0
6.2
44.0
7.3
60.0
7.3
56.0
10.6
52.0
8.4
44.0
13.9
44.0
5.1
48.0
7.3
48.0
10.6
40.0
12.8
52.0
7.3
40.0
8.4
44.0
4.0

Design
AF
point (m3/h)
34
51.0
35
39.0
36
47.0
37
63.0
38
39.0
39
35.0
40
43.0
41
51.0
42
59.0
43
55.0
44
47.0
45
35.0
46
35.0
47
35.0
48
39.0
49
43.0
50
39.0
51
47.0
52
55.0
53
43.0
54
39.0
55
35.0
56
63.0
57
59.0
58
39.0
59
55.0
60
75.0
61
47.0
62
67.0
63
63.0
64
55.0
65
55.0

IT
SR
(˚C) (g/min)
48.0
8.4
68.0
6.2
56.0
7.3
52.0
4.0
44.0
12.8
52.0
11.7
68.0
5.1
60.0
5.1
48.0
6.2
56.0
5.1
44.0
10.6
68.0
7.3
80.0
4.0
76.0
5.1
56.0
9.5
64.0
6.2
60.0
8.4
40.0
11.7
52.0
6.2
44.0
11.7
40.0
13.9
72.0
6.2
48.0
5.1
56.0
4.0
64.0
7.3
60.0
4.0
40.0
4.0
68.0
4.0
40.0
6.2
44.0
6.2
40.0
9.5
44.0
8.4

2.2.6 Evaluation of the First Principle Control
The first principle control using EEF was expected to effectively regulate the drying
environment. The in-process materials were expected to have similar water content if they were
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produced in a similar drying environment. NIR was employed to examine the water content of inprocess materials, due to its sensitivity to water and capability of rapid in-line analysis (Burns and
Ciurczak, 2001).
Six batches were produced under the ambient conditions displayed in Table 2.4. Batches
1, 4, and 5 were operated using basic control, whereas the rest were by Simplex control. Note, the
decrease of RH along with the sequence of batch production resulted from the time of year at
which experiments were performed. Batches 1 and 2 were manufactured in summer (July), batch
3 and 4 were in fall (September), and batch 5 and 6 were in winter (January).
The NIR spectra for the spraying phase of each batch were analyzed by principal
component analysis (PCA). Batches 1 and 2 were used to build the PCA calibration models for the
basic control and Simplex control, respectively. The spectra were preprocessed by Standard
Normal Variate (SNV) and followed by mean-centering. The purpose was to remove the baseline
variation associated with the fluidization, and emphasize on the absorbance change. If the
predictions of the test batches are similar to the calibration, the drying environments of the three
batches are considered similar.
Table 2. 4 The ambient conditions of batches produced using the basic control and Simplex control

Control mode

PCA model
Calibration

Basic control
First principle
control

Test
Calibration
Test

Batch
number

Ambient RH
(%)

Ambient
temperature (°C)

1
4
5
2
3
6

67.8%
24.0%
16.6%
72.8%
26.5%
10.5%

20.4
21.1
21.7
20.2
22.0
19.8
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2.3 Results and discussion
2.3.1 Basic Control and Calculation of EEF
The acceptable process settings were discovered for the basic control. Figure 2.5 (A) shows
a typical process trajectory operated using the settings listed in Table 2.5. The greater variation
observed in AF (blue) than IT (red) was attributed to the pressure drop of the fluidized bed system
for cleaning the filter house. Product temperature (PT) was indicated by green circles and observed
in a range of 35-40 ˚C throughout the process at steady state, indicating the stability of the process
(Larsen et al., 2003; Lorck et al., 1997a; Wesdyk et al., 1990). Note that the acceptable batches
were all produced in winter under similar ambient conditions: temperature range 19-21 ˚C and RH
of 10-20%. However, the discovered process settings were found non-operational when they were
applied to the processes produced in a different season. Four batch failures, resulted from wet
quenching, were obtained in a total of 13 batches produced during the fall. The batch failures all
occurred at the RH greater than 60%. The result was attributed to the susceptibility of the drying
capacity to the variation in ambient humidity. Because the basic control did not have a control
mechanism to compensate for the change in ambient humidity, its drying capacity was only
determined by the humidity ratio of the inlet air.
Table 2. 5 Process setpoints for the drug layering process using basic control.

Process setpoints
AF (m3/h)
IT (˚C)
SR (g/min)
AP (bar)

Preheating
40
55
0
0

Phase
Spraying
Drying
50
40
60
65
5
0
1.6
0
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Cooling
35
21
0
0

Figure 2. 5 Basic control and EEF calculation. A: Process measurements under the basic control; B: Calculated EEF
based on the process parameters of basic control.

The EEF values were calculated using the measured process parameters. Note, the EEF
was used to describe the drying environment for the coating process, and therefore it was only
calculated for the spraying phase. The calculated EEF values of the process shown in Figure 2.5
(A) were presented in Figure 2.5 (B). The observed fluctuations were due to the common cause
process variance. A mean EEF of 0.64 with a standard deviation (SD) of 0.05 were obtained from
six batches produced under the basic control. The EEF of 0.64 was used as the target value for
developing the first principle control in subsequent studies.

2.3.2 First Principle Control Algorithm
Control algorithms of univariate and Simplex were developed to implement the first
principle control approaches. A typical process manipulated by univariate control is shown in
Figure 2.6. The example used IT as the control input. The IT setpoints were calculated by Eq. (2.2),
and are highlighted in red circles. The measured IT (yellow triangles) display random oscillations
around the setpoints. The deviations were attributed to the inherent variability of the heater. A
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variation of 6 ˚C was observed even when the IT setpoint was held constant. The variation resulted
from the latency of the heating system. The heater used a binary switch, which was turned either
fully on or fully off. It took approximately 30 s to heat or cool the inlet air to the desired
temperature. The deviation is expected to be inhibited by using a heating system with reduced
latency.

Figure 2. 6 Univariate control using inlet air temperature.

Hypothetically, univariate control can also be achieved by manipulating AF or SR. The
effects of each manipulated parameter on the EEF calculation are shown in Figure 2.7. The
relationships were obtained by changing one manipulated parameter while maintaining all other
process parameters at constant. Increasing IT and/or AF decrease EEF and therefore lead to a
greater drying capacity. In contrary, increase of SR causes an increased EEF and lowers the drying
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capacity. Nevertheless, the desired AF setpoints often exceeded its operable limit due to its
relatively weak influence on the drying environment as evidenced by Figure 2.7. On the other hand,
a slight change in SR exerted a tremendous impact on the thermodynamic environment, due to the
high latent heat of vaporization of water. Although conceptually possible, it was practically
difficult to exclusively use AF or SR to develop a univariate control system.

Figure 2. 7 Independent effects of IT, AF, and SR on EEF while all other process parameters are constant.
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The fluidized bed system had a faster adjustment for AF and SR. A setpoint of AF and SR
can be reached in 5 s or less. The fast adjustment of the AF and SR compensated for the latency
associated with the IT. This allowed the development of the Simplex control with the goal of
improving the operability for controlling the EEF. The Simplex control simultaneously adjusted
all the manipulated parameters to operate the process, which can be seen in Figure 2.8. The results
were obtained from three batches differentiated in colors. Despite the significant changes in the
setpoints of each manipulated parameter, the EEF outputs of all the three batches are normally
distributed (Figure 2.9). The mean of EEF outputs (0.66) is effectively controlled at the EEF target
(0.64).
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Figure 2. 8 Setpoints of manipulated parameters commanded by Simplex control. From top to bottom: setpoints of air
flow; inlet air temperature; spray rate.
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Figure 2. 9 EEF outputs of three batches versus EEF target of 0.64.

It was hypothesized that the Simplex control would improve the operability of controlling
the EEF compared to the univariate control. The control errors of the univariate and Simplex
control are overlaid in Figure 2.10. The Simplex control (green) had a lower variation (SD = 0.051)
than the univariate control (red) (SD = 0.086), indicating a more precise control of the EEF and
therefore supported the hypothesis. The errors of the univariate control appear bi-normally
distributed. The control accuracy of the EEF was highly dependent on whether the manipulated
parameters can be precisely maintained at their setpoints. However, the intrinsic over-shooting and
over-cooling problems of the heating system lead to a significant bias in IT, which was propagated
to the calculation of the EEF outputs. This may explain the observed bi-normal distribution.
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Figure 2. 10 Comparison of the control errors between Simplex and univariate control algorithms

2.3.3 Comparison of the Drying Environment Between Basic Control and Simplex
Control
A significant difference in the drying environment was found when the basic control was
used. The PCA scores of NIR of batches 4 and 5, though operated under the same process
conditions of batch 1, are on the outside of the confidence interval defined by the PCA calibration
(Figure 2.11 (A)). The Q residual contribution plot is often used to identify the sources of model
uncaptured variance. Extraordinary contributions from the regions of 1400-1500 nm and 19001950 nm were observed; the Q residuals of the test batches are approximately 10 times larger than
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that of the calibration batch (Figure 2.11 (B)). These wavelength ranges, characteristic of O-H first
overtone and combination bands, are typical fingerprint regions indicating water absorption. A
new PCA model was calculated by excluding the water-characteristic regions. After the truncation,
the scores of the test batches were similar to the calibration (Figure 2.11 (C)). Further examination
of the Q contribution plot shows the uncaptured variance is mainly from 1600-1800 nm (Figure
2.11 (D)), characteristic of the first overtone of C-H, C-H2, C-H3, and Ar-CH. The uncaptured
variance was speculated to be due to the between-batch variation of the drug content.
In contrast, the batches produced by the Simplex control did not demonstrate the variability
in water content observed in the basic control batches. The PCA calibration model was built with
full NIR spectrum. The pattern of the PCA scores of the test batches are very close to the
calibration (Figure 2.11 (E)), indicating the NIR spectra of the in-process materials across the three
batches were similar. The Q residuals of all three batches are similar (Figure 2.11 (F)). However,
it should be noted that the PCA calibration of the Simplex control captured significantly less total
variance (X-variance of 84.7%) compared to the basic control (X-variance of 95.4%). This can be
explained by the difference in the process manipulation. The basic control used the same process
settings, and therefore the variation carried in NIR spectra was primarily associated with the
increase of APAP. Unlike the basic control, constantly changed process settings were executed by
the Simplex control. The frequent changes in air flow velocity and liquid addition rate may have
complex impacts on the NIR spectra. The fluidization bubbles formed at different air flow velocity
have varied size and distribution, which may affect the path lengths of NIR reflectance. The change
in liquid addition rate lead to significant difference in NIR absorbance because the coating material
and water were applied at inconsistent speed. The additional variation resulted from the process
manipulation lead to a more challenging interpretation of the PCA result.
53

More importantly, the Simplex control effectively eliminated the batch failures. Four batch
failures were observed in a total of 13 batches produced using the basic control. Even the
successful batches gave a broad EEF range of 0.40-0.85, indicating significant variability of the
drying environment produced using the basic control. The four batch failures were caused by defluidization associated with wet-quenching and all occurred at RH greater than 65%. In contrary,
no batch collapse was observed in the 32 drug layering batches manipulated by the Simplex control.
The Simplex control gave an average EEF of 0.66 for batches manufactured at a RH range of 875%. The between-batch RSD of the mean EEF was 2.69% The results indicate the Simplex
control successfully reduced the batch failures by maintaining a consistent drying environment.
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Figure 2. 11 PCA of NIR data collected during spraying phase. A-B: NIR of basic control with full spectrum; C-D:
NIR of basic control after variable truncation; E-F: NIR of Simplex control.
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2.4 Conclusion
The development of the first principle control (Simplex control) has achieved the goal of
reducing batch failure and improving process robustness against the variation of ambient humidity.
Acceptable process settings of the investigated process under the basic control were determined.
However, the basic control failed to ensure the long-term success of the process. Several batch
failures resulted from wet quenching; these were observed when the coating process was
manipulated using the same settings but in a different season. The failure of using the basic control
was attributed to the susceptibility of the drying capacity to the variation in ambient humidity.
In the first principle control approach, the traditional process settings were replaced by EEF
setpoint. An average EEF of 0.64 was acquired from six successful batches operated under the
basic control, and used as the process target for process operation. Univariate and Simplex control
algorithms were designed to execute process manipulation. The univariate algorithm only used IT
to adjust the process to reach the EEF target. The Simplex algorithm was further established by
adjusting three manipulated parameters simultaneously to improve control efficiency and accuracy
of maintaining an EEF target. Despite the process settings changing continuously, the EEF outputs
were normally distributed with the mean effectively controlled at the target value of 0.64. A further
comparison between the two control algorithms revealed that Simplex had lower control errors
and variance. Therefore, the Simplex algorithm was implemented in the first principle control
system.
The effect of the Simplex control on maintaining a constant drying environment was
examined by PCA analysis of in-line NIR spectra. The PCA model showed a significant difference
between the batches produced using the basic control. The model-unexplained spectral variance
was attributed to the variation of the water content of the in-process materials during coating. In
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contrast, the three batches of Simplex control had similar spectral properties across all batches as
evident from the PCA analysis. No extraordinary source contributing to the Q residual was
identified. In subsequent studies, the Simplex control produced 32 successful batches without a
single batch failure, as opposed to the basic control which had a failure rate of approximately 30%.
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Chapter 3: Develop Empirical Analytical Models for Process
Monitoring of Pellet Coating
3.1 Introduction
The work in chapter 2 successfully addressed the issues previously encountered in the
operation of drug layering process. The Simplex algorithm controlled the EEF effectively at its
target value to provide a consistent drying environment. It succeeded in maintaining the process
in a state of control and eliminating batch failure. Nevertheless, the Simplex determined the
process endpoint by applying a fixed amount of coating liquid across all the batches. This
conventional method for determining the process endpoint ignored the process variation in coating
efficiency, therefore may compromise the consistency of product quality.
An in-line process monitoring system is desired to ensure the product quality. By
developing real time quantitative analysis, the CQA can be monitored in real time and used to
feedback the control system to determine the process endpoint when the desired quality
specifications are met. Establishing such process monitoring system requires a potential analytical
technique to provide rapid and non-destructive measurement while able to be incorporated in a
process stream.
Near-Infrared (NIR) and Raman spectroscopy are increasingly used in the pharmaceutical
industry. They have been successfully applied to determine the quality attributes of coating
products (Andersson et al., 1999; B.R. Buchana et al., 1996; Kirsch and Drennen, 1995). The most
prominent absorption bands in the NIR region are related to the overtones and combinations of
fundamental vibrations of C-H, N-H, O-H and S-H functional groups.(Burns and Ciurczak, 2001)
Raman spectroscopy is sensitive to the conjugated double bonds, aromatic rings and other
characteristics of chemical structures present in most active substances (Neuberger and Neususs,
58

2015). Both techniques offer efficient and non-destructive measurement with minimal sample
preparations. Given the advantages provided by the two techniques, NIR and Raman spectroscopy
were considered as suitable techniques for developing the process monitoring system.
Both NIR and Raman are indirect methods. Empirical modeling is required to calibrate the
NIR and Raman spectra to the reference measurements. The calibration model is subsequently
used to predict the CQAs to achieve quantitative analysis. Therefore, the work in this chapter
focused on developing empirical analytical models using NIR and Raman spectroscopy to achieve
process monitoring of the drug layering process. The goals of this study were to (1) build
preliminary empirical analytical models using NIR and Raman spectroscopy, (2) select a more
suitable technique based on the performance of the models and develop robust empirical models,
and (3) apply the robust model to monitor the drug layering process and examine its capability for
ensuring product quality.

3.2 Materials and Methods
3.2.1 Drug layering Process and Sample Collection
The formulation of the drug layering pellets, fluidized bed system, and process
measurement were described in chapter 2. A total of 15 batches were produced in the work of this
chapter. The process was operated using the Simplex control. The spraying was terminated when
the same amount of drug layering suspension (350 g) was applied. Drug layered pellets were
withdrawn from the process during fluidization using a built-in sample thieve at predetermined
time point. The samples taken during the spraying phase were used for building empirical
analytical models. End product samples were also collected after a complete process, which were
used for assessing the model performance.
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3.2.2 Drug Content Determination
The drug layered content was determined by the ultraviolet-visible (UV) spectroscopy (HP
8453, Agilent Technology, Santa Clara, CA). Acetaminophen (APAP) standard solutions of five
concentrations were prepared (Table 3.1) by dissolving the required amount of APAP in deionized
water. Three replicates of each standard solution were scanned at 243 nm, and the mean value of
the absorbance was used to calculate the calibration curve. The repeatability of the UV method
was assessed to ensure the precision, and expressed as relative standard deviation (RSD). The
samples for UV analysis were taken from the drug layering process at predetermined time. Three
replicates of each sample were analyzed by the UV method to determine the drug content. Each
replicate was weighed at about 400 mg.
Table 3. 1 UV method development of APAP.

Theoretical Concentration (mg/mL)
0.001
0.002
0.003
0.010
0.014

Mean Absorbance
0.053
0.119
0.205
0.626
0.862

Repeatability (RSD)
0.115%
0.005%
0.064%
0.062%
0.065%

3.2.3 In-line Spectroscopic Data Collection
The NIR measurement and data collection were described in chapter 2 (section 2.2.2). The
Raman spectra were collected using a RXN2 Hybrid analyzer (Kaiser Optical Systems, Ann Arbor,
MI) with a thermoelectrically cooled charge-coupled detector. A schematic diagram of the Raman
sensor setup from side view is shown in Figure 3.1 (A). The laser source was operated at 785 nm
with a laser power of 600 mW. The spectrometer was equipped with a non-contact optic sampling
device (PhAT probe). The excitation light passing through the optical fibers is collimated by a lens
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and imaged onto the sample to form a circular illumination area of 6 mm diameter. The PhAT
probe was attached to the exterior observation window, where the probe was covered by aluminum
foil to prevent laser exposure (Figure 3.1 (B)). The Raman data were collected at a frequency of
0.2 Hz with an exposure time of 3 s. The Raman spectrum had a wavenumber range of 150-1890
cm-1 and spectral resolution of 1 cm-1 increment. Note, both NIR and Raman spectra were collected
from the batches produced using the Simplex control.

Figure 3. 1 Setup of Raman data collection. A: Side-view, B: Laser exposure prevention.

3.2.4 Empirical Model Development
Empirical analytical models using spectroscopy were established by relating the spectra to
the reference values using partial-least-squares (PLS) regression. The reference values were results
obtained using UV analysis. The mathematical computation was performed using MatLab
(R2014b, The Mathworks Inc., Natick, MA) and PLS_Toolbox (Eigenvector Research Inc.,
Manson, WA). The empirical analytical models were developed in two steps. First of all,
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preliminary NIR and Raman models were built using a small data set. Two batches were used to
build a calibration model for each technique, and one batch was used to test the calibration model.
Based on the results of the preliminary models, the technique offering greater model performance
(calibration and prediction errors) was selected to develop a robust model.
According to ICH Q2, a desirable analytical model is expected to show the reliability of an
analysis, with respect to deliberate or expected variations in the method. If the measurements are
susceptible to the variations in analytical conditions, the conditions should be suitably
controlled.(FDA, 1996) The processes produced by the Simplex control were expected to have
greater process variance, because the algorithm simultaneously adjusted the setpoints of all the
manipulated parameters, including air flow (AF), inlet air temperature (IT), and spray rate (SR).
To make the model robust against the process variance, the batches used for building the
calibration model were required to have a greater range of each manipulated parameter. Table 3.2
shows the ranges of the setpoints of all the manipulated parameters. The ranges of AF, IT and SR
of the calibration data set are broader than the test and validation.
Table 3. 2 Ranges of the process setpoints of calibration, test, and validation

Data set

Ranges of the setpoints

Number of
batches

AF

IT

SR

Calibration

6

35.6-69.3 m3/h

47.0-80.0 °C

4.5-5.9 g/min

Test

3

40.0-61.8 m3/h

54.5-76.4 °C

4.5-5.5g/min

Validation

3

40.0-58.2 m3/h

54.5-76.4 °C

4.5-5.6g/min

A total of 96 samples were collected from the 12 batches. Table 3.3 shows the details of
the sampling protocols. Batches 1-6 were used for calibration, batches 7-9 were for test, and
batches 10-12 were for validation. The samples were taken from each batch at predetermined time,
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in an average of every 10 min. The calibration model was built using 24 samples randomly selected
from batches 1-6 (highlighted in yellow). Twelve samples were randomly selected for test and
validation, which are highlighted by blue (test) and green (validation) in the table.
Table 3. 3 Samples for calibration, test, and validation.

Dataset

Calibration

Test

Validation

Batch #
1
2
3
4
5
6
7
8
9
10
11
12

5
10
5
10
5
10
5
10
5
10
5
10

15
20
15
20
15
20
15
20
15
20
15
20

25
30
25
30
25
30
25
30
25
30
25
30

Sampling time (min)
35
45
40
50
35
45
40
50
35
45
40
50
35
45
40
50
35
45
40
50
35
45
40
50

55
60
55
60
55
60
55
60
55
60
55
60

65
70
65
70
65
70
65
70
65
70
65
70

End
End
End
End
End
End
End
End
End
End
End
End

End: spraying endpoint when 350g APAP suspension was applied

Various modeling conditions (data preprocessing, variable selection, number of latent
variable (LV), etc.) were attempted. The model performance was assessed with respect to the errors
of calibration, cross-validation, and prediction. Note, the model input (X) and response (Y) refer
to the spectra and drug content, respectively. The calibration error, expressed as the root-meansquare error (RMSE) of calibration (RMSEC), was calculated by Eq. (3.1),

𝑅𝑀𝑆𝐸𝐶 =

∑

(

)

Eq. 3.1

where 𝑦 is the drug layering content determined by UV method, 𝑦 is the model prediction by the
NIR or Raman model, 𝑛 is the number of samples in the calibration, and 𝐴 is the number of
included LV. The cross-validation was performed by random subset method, and the error
(RMSECV) was calculated as,
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∑

𝑅𝑀𝑆𝐸𝐶𝑉 =
Here 𝑦

,

(

,

)

Eq. 3.2

is the estimate for 𝑦 based on the calibration equation with sample i deleted. The

calibration model was optimized by minimizing the RMSEC and RMSECV. The prediction error
(RMSEP) of the optimized model was obtained by,
∑

𝑅𝑀𝑆𝐸𝑃 =

(

)

Eq. 3.3

For the development of a robust model, permutation tests were performed to examine risks
of overfitting. Permutation tests provide a probability that the given model is significantly different
from one built under the same conditions but on random data. Permutated models are repeatedly
obtained by relating the model input (X-block) to the responses (Y-blocks) which were randomly
reordered (shuffling). For a regression problem, this means each sample is assigned a nominally
"incorrect" Y value (although the distribution of Y values is maintained because every sample's Y
value is simply reassigned to a different sample). After each permutation of the Y-block, the
predictions for each sample by cross-validation and self-prediction (calibration), and the RMSEC
and RMSECV are recorded. The shuffling is repeated multiple times and several statistics are
calculated for each permutation. The result is reported in two forms: A table of probability of
model insignificance, and a plot of fractional sum squared Y (𝑆𝑆𝑄 ) versus Y-block correlation.
The 𝑆𝑆𝑄 can be calculated from RMSEC and RMSECV,
𝑆𝑆𝑄

,

,

=1−

where 𝑆𝑆𝐸

,

Eq. (3.4)

,

is the sum squared error in Y self-prediction (by calibration), 𝑆𝑆𝑄

,

is the total

sum squared Y. For cross-validated predictions,
𝑆𝑆𝑄

,

=1−

,

Eq. (3.5)

,
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The developed robust model was subsequently used to monitor the drug layering process.
The spraying phase automatically ended when the predictions of the drug layered content reached
the target limit. The target was set at 0.035 (w/w), or 3.50%, which was a ratio of layered drug
content over the pellet weight. The drug layered content of the end products was validated using
UV method.

3.3 Results and discussion
3.3.1 Preliminary Model Development
The NIR and Raman spectra of pure components in the drug layered samples were
examined to compare the selectivity of the techniques. Figure 3.2 (A) displays the Raman spectra
of pure components, APAP, HPMC, and core pellet. Note the spectra were normalized and offset
for visualization. APAP and core pellet have multiple distinct features as evidenced by the sharp
signals observed in the whole Raman region of 150-1700 cm -1. Although dominated by the broad
and overlapping features, distinguishable absorbance of APAP is still visible in the region of 16001700 nm (Figure 3.2 (B)).

Figure 3. 2 Pure spectra of APAP, HPMC, and core pellet. A: Raman spectra; B: NIR spectra.
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The correlation of spectral change and the increase of drug content was investigated for
each technique, by comparing the spectra of coated pellets with the pure spectra of APAP and core
pellet. Because the amount of APAP was very small compared to the mass of the core pellets, two
drug layering batches coated up to 5 hours (approximately corresponding to a drug content of 0.16
(w/w), or 16%, were produced and used for the comparison study. The Raman and NIR spectra of
samples coated at a given time are overlaid with their pure spectra and shown in Figure 3.3. The
change in Raman spectra (Figure 3.3 (A)) is dominated by the diminished signal of the core pellet.
Decreased Raman signal was observed in most of the spectrum regions that are characteristic of
the core pellet, particularly at 400 cm-1, 443 cm-1, 476 cm-1, 524-552 cm-1, etc. Limited increase of
spectra was observed in regions indicating APAP, such as 610 cm-1, 800 cm-1 and 969 cm-1, etc.
Although Raman is often deemed having greater selectivity than the NIR (Févotte, 2007), its weak
signal of APAP, which was interfered by the core pellet, compromised its advantage.
Unlike Raman, the NIR spectra had a much stronger correlation with the increase of APAP.
Significant increase of NIR absorbance was found in the wavelength range of 1600-1700 nm,
which is distinctly associated with APAP. The result suggested NIR spectroscopy has much
stronger signal and is more sensitive to APAP. Although NIR spectroscopy is often criticized for
having less selectivity, it is noteworthy that the selectivity should be concluded by taking into the
consideration of the overall formulation system. In the current drug layering system, the NIR
spectrum showed distinct APAP spectral features without noticeable interference from other
ingredients. Therefore the NIR spectroscopy was considered selective to APAP.
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Figure 3. 3 Spectra of pellets coated for different time versus pure spectra of APAP and core pellet. A: Raman spectra;
B: NIR spectra.

Preliminary Raman and NIR models were calculated and optimized using the methods
described in section 3.2.4. The methods and performance results of the preliminary models are
displayed in Table 3.4. The NIR model outperformed the Raman model, which was supported by
its lower calibration error (RMSEC) and prediction error (RMSEP). The prediction error of NIR
model (RMSEP = 6.76%) was similar to its calibration error (RMSEC = 5.68%) and crossvalidation error (RMSECV = 7.57%). Note the errors are expressed in percentages by normalizing
to the calibration range, this form applies to the whole dissertation. Unlike the NIR method, the
RMSEP of Raman (19.71%) was approximately three times higher than the RMSEC (7.43%),
indicating a poor prediction performance. Figure 3.4 shows the prediction of Raman model (Figure
3.4 (A)) has a much larger prediction bias (12.86%), as opposed to the limited bias (1.62%)
provided by the NIR model (Figure 3.4 (B)).
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Table 3. 4 Modeling conditions and model performance of preliminary Raman and NIR models.

Preliminary comparison
Variable selection

Model
development
methods
Model
performance
results

Preprocessing
Number of latent variables
RMSEC (w/w)
RMSECV (w/w)
RMSEP (w/w)
Prediction bias

Raman
250-1862 cm-1
Normalization
First-derivative
Mean-center
2
7.43%
8.86%
19.71%
12.86%

NIR
1085-2225 nm
MSC
Mean-center
2
5.68%
7.57%
6.76%
1.62%

Figure 3. 4 Predictions versus measurements of preliminary models. A: Raman model; B: NIR model.

The preliminary Raman model failed to provide adequate predictions. The Raman
calibration model captured reasonable co-variance: X-variance of 96.81% and Y-variance of
92.55%. Nonetheless, the systematic error indicated the Raman calibration model did not capture
sufficient batch to batch variance by using data from only two batches. Besides its inherent
drawback of weak signal, the result may also be explained by its susceptibility to the variations in
process interface. Unlike the way of immersing the NIR probe into the bulk of pellets, the Raman
probe was mounted manually to the exterior observation window. The sensor was removed from
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the equipment when the process was completed, and reinstalled ahead of time before a new
experiment. The PhAT probe has a spot size similar to the width of the observation window,
therefore a slight variation of the sensor position may lead to capturing irrelevant information.
Moreover, reinstalling the probe may change the angle of the probe and affect the camera focus.
Based on the comparison of the preliminary results, NIR spectroscopy was selected to develop a
robust model with the purpose of implementing it to the hybrid control system to allow long-term
use. It should be noted that the result in the preliminary study did not rule out the possibility of
developing adequate Raman method for other systems.

3.3.2 Robust Model Development
The robust NIR model was developed under the modeling conditions: preprocessing the
spectra in the wavelength range of 1146-2076 nm by using SNV and mean-centering. The number
of LVs included in the model was preliminarily determined based on the plot in Figure 3.5 (A).
The minimized RMSEC and RMSECV were obtained when three LVs were included. To confirm
the preliminary conclusion, the results of the permutation tests were examined for testing
overfitting. The idea is if the selected model conditions are overfitted, they often provide a fit to
random data which is better than would be expected. The permutation examines the extent the
modeling conditions might be finding "chance correlation" between the X-block and Y-block.
The SSQ plot (Figure 3.5 (B)) shows the fractional Y-variance captured for calibration and
cross-validation versus the correlation of the permuted Y-block to the original Y-block. Note the
𝑆𝑆𝑄

,

and 𝑆𝑆𝑄

,

are expected to increase up to a value of “1” when the model is capturing all

the Y-block response. The 𝑆𝑆𝑄

,

and 𝑆𝑆𝑄

,

are shown in centered and standardized form, the
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perpendicular axis of any model’s result indicates how far away from the data mean that point is
in standard deviations. In general, the cross-validation and self-prediction (calibration) values
should be relatively close to each other, but should be significantly less than the results for the
non-permuted Y-block (on the far right side of the plot). The further away the un-permuted results
are from the mean, the more unlikely that the original model is overfitted. The standardized 𝑆𝑆𝑄
of the un-permuted model indicates the nth standard deviation at which the original model can be
considered to fall. For a model using three LVs, a standardized 𝑆𝑆𝑄

,

of 2.06 and 𝑆𝑆𝑄

,

of 1.79

were obtained for the calibration and cross-validation, respectively. The two values dropped to
1.62 and 1.19 when the fourth LV was included. The higher the standardized 𝑆𝑆𝑄 values, the
more likely that the original model is significant and not overfitted.

Figure 3. 5 Selection of LVs. A: RMSEC and RMSECV versus number of LVs; B: Permutation plot of sum squared
fractional Y-variance captured by the calibration and cross-validation.

The probability table (Table 3.5) shows the probabilities (calculated using several different
methods including Wilcoxon and pairwise signed rank test (Thomas, 2003), and randomization ttest (van der Voet, 1994)) that the predictions for the original, unperturbed model could have come
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from random chance. Put another way: the probabilities that the established model is not
significantly different from one created from randomly shuffling the Y-block. The result is
reported as a probability that the models are not distinguishable at the given probability level. Thus
a value of 0.05 indicates that the models are indistinguishable at the 5% limit, which is equivalent
to saying they are significantly different at the 95% limit. The results of the permutation test
probabilities indicated the most significant model was built using three LVs.
Table 3. 5 Probability of model insignificance of permutation test.

Number of LV

2
3
4

Methods

Wilcoxon

Sign test

Rand t-test

Self-prediction
Cross-validated
Self-prediction
Cross-validated
Self-prediction
Cross-validated

0.014
0.005
0.002
0.002
0.002
0.004

0.073
0.044
0.016
0.017
0.017
0.014

0.014
0.009
0.008
0.006
0.008
0.011

Wilcoxon: pairwise Wilcoxon signed rank test
Sign test: pairwise signed rank test
Rand t-test: randomization t-test

The optimized model gave a RMSEC of 7.78%, RMSECV of 11.02%, and RMSEP of
7.08%. The model fittings are shown in Figure 3.6 (A), and the LVs are overlaid in Figure 3.6 (B).
The first LV (red) explained 57.72% of X-variance and 65.33% of Y-variance. The more evident
weights of LV 1 (red line) are in the regions (1600-1700 nm and 1400-1450 nm) relating to APAP
(magenta dashed line) and core pellet (black dashed line), respectively. Extraordinary weights on
1900-2000 nm of LV 2 (blue line) are presumably associated with the core pellet and HPMC. LV3
starts to show noisy features which can be explained by capturing only 3.90% of X-variance.
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However, it captured 10.98% of Y-variance. The regions showing noticeable weights were related
to the absorbance of core (1400-1450 nm) and possibly variation in the water content (1890 – 1940
nm). Nevertheless, it may also reflect spectra changes associated with the physical effect such as
increases of particle size.
The robust NIR model captured less Y-variance (86.96%) than the preliminary model
(92.55%). The two batches used for developing the preliminary calibration model were produced
at similar ambient RH (52.90% and 55.20%). Therefore, the Simplex control provided nearly
identical process settings, leading to similar NIR spectra collected. In these batches, the increase
of APAP was the only factor that has significant influence on the NIR spectra. On the other hand,
the process settings used for producing the six batches for building robust model had very broad
ranges, because the large variation of the ambient RH (10.60%-72.90%). The continuously
changed process settings lead to more spectral variance, which did not contribute to the co-variance.

Figure 3. 6 Robust NIR model development. A: Predictions versus measurements; B: LVs overlaid with pure spectra
of APAP, HPMC, and core pellet.
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3.3.3 Process Monitoring
The robust model obtained was subsequently applied to monitor the drug layering process.
Figure 3.7 (A) shows a prediction trajectory monitored by the robust NIR model. The green squares
represent the NIR predictions during spraying, while red and blue symbols indicate the predictions
during pre-heating, and drying and cooling. The model diagnostic plot in Figure 3.7 (B) indicates
the predictions are well confined to the confidence interval of the NIR calibration model,
suggesting the batch was in a state of control. The spraying automatically ended when the
predictions reached the predefined target of 0.035 (w/w). Because the NIR model was established
only using drug layered samples, therefore any predictions outside the spraying phase were model
extrapolations, which may explained the bias of 0.005 (w/w) observed at the start of the process
shown in Figure 3.7 (A).
The goal of the process monitoring system was to accurately predict the CQAs in real time
and allow process endpoint determination. The UV method determined a mean drug content of
0.0333 (w/w) from nine end product samples (three replicates per three batches), while the NIR
model gave a mean prediction of 0.0352 (w/w). The bias was mainly due to the drug loss caused
by attrition. Subsequent studies showed an average 2.70% drug loss due to the attrition.
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Figure 3. 7 Process monitoring of drug layering process. A: Predictions of drug layered content by NIR model; B:
Model diagnositic of Q residuals versus Hotelling’s T 2.

The real time process monitoring proved its capability to detect abnormal event during the
process. The predictions in Figure 3.8 (A) shows an irregular plateau starting from 36 min, which
was caused by nozzle fouling. A continuous prediction trend appears again at 60 min after
resolving the nozzle issue. Figure 3.8 (B) shows aberrant changes of the EEF appear at about 45
min. The delay in time was attributed to the mechanism of control algorithm. The Simplex control
used all the manipulated parameters to maintain the EEF at its preset target, therefore, it was robust
to the changes in the process environment. An abrupt change of the EEF output showed up only
when the calculated setpoints of the manipulated parameters exceeded the operable limits. The
Simplex control’s capability of maintaining the EEF at the target compromised its detectability of
abnormal changes. However, the process monitoring method proved it was able to offset the
drawback. NIR spectroscopy is sensitive to the change in chemical attributes of in-process
materials. The sensitivity allows it to detect unusual process changes at a much early stage. With
this capability, the NIR-based process monitoring offers chances to bring a deviating process back
to the state of control, and therefore is useful to reduce batch failure and ensure product quality.
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Figure 3. 8 Process monitoring of drug layering process. A: Predictions of drug layered content by NIR model; B:
EEF outputs.

3.4 Conclusion
An empirical NIR model was successfully established using in-line NIR spectroscopy to
monitor the drug layering process. A comparison between NIR and Raman spectroscopy was made
by building preliminary calibration models using a small data set (two batches per method). The
NIR calibration model outperformed the Raman model, as evidenced by its RMSEP (6.76%) three
times smaller than Raman (RMSEP of 19.71%). Therefore, NIR spectroscopy was perceived as a
more suitable technique for developing the process monitoring method in this work.
A robust NIR calibration model was developed using a larger data set collected from six
batches. The optimized model, chosen based on the results of permutation tests, gave a RMSEP of
7.08%, which was similar to the RMSEC (7.78%). The NIR model proved its capability to monitor
the drug layering process. For a normal process, the model provided predictions of the drug content
to determine the process endpoint. The spraying phase was automatically terminated when the
predictions reached the target drug load of 0.035 (w/w). The average of the NIR predictions was
greater than the UV measurements with a bias of 0.0019 (w/w), or 5.40% if normalized to the drug
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content. The error was primarily attributed to the drug loss caused by attrition during the drying
and cooling phases.
The empirical NIR model achieved the goals of monitoring the drug layering process by
providing real time quantitative analysis of drug content. The model also demonstrated its value
of early problem detection. An abnormal event resulted from nozzle fouling was successfully
detected by NIR at a much earlier stage than using the EEF output from the Simplex control. This
was helpful to offset the shortcomings of the Simplex control in detecting anomalous event during
the process. However, it should be noted that the effectiveness of the problem detection depends
on the sensitivity of the NIR spectrum to the changes in the process. Because NIR has a high
sensitivity to material attributes, it can rapidly respond to the changes that directly affect the
properties of the coated pellets. Its ability of detecting abnormal event may not be as prominent in
cases such as forming many small agglomerates without causing batch failures, as the physical
changes often shown up in baseline variation and therefore are more difficult to be detected.
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Chapter 4: Develop Hybrid Process Control System by Integrating
Process Manipulation, Monitoring and Optimization
4.1 Introduction
Process manipulation and monitoring methods were successfully developed in chapter 2
and 3, respectively. The Simplex control effectively eliminated batch failure by maintaining a
consistent drying rate across all the batches. The empirical NIR model provided real time
quantitative analysis of drug content to determine process endpoint. Notwithstanding the
demonstrated capabilities of improving process operation and quality assurance, the drug layering
processes were still not controlled under the optimum conditions. Therefore, the work in this
chapter centers on the last step of developing the hybrid control system: process optimization.
The goal of process optimization was to discover the optimum setpoints in a design space .
Design space is defined as a multidimensional parametric space within which acceptable quality
product is obtained (FDA, 2009). Different approaches can be considered when implementing a
design space (e.g., process ranges, mathematical expressions, or feedback controls to adjust
parameters during processing). It is typically built by statistical modeling from design of
experiment (DOE). The DOE provides knowledge and understanding of the relations between
process factors and outputs, which contributes to the design space implementation and continuous
process improvement.
In the presence of process variations, the risk of failing to meet specifications is higher
when operating the process near the edges of the design space (Little, 2014). It is helpful to
determine the edges of failure, beyond which the specifications cannot be met. By taking into
account the process variability, operation space can be identified at a specified confidence level
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depending on the needs of the process. It can be graphically illustrated as a smaller region situated
in the design space with greater confidence to meet specifications. Therefore, OS was proposed to
achieve process optimization.
The goals of the study in this chapter had three folds: (1) understand the relations between
process factors and quality attributes of interest by developing a design space, (2) establish OS to
achieve process optimization, and (3) compare the process capability of the proposed hybrid
control system with the basic control.

4.2 Materials and methods
4.2.1 Drug Layering Process and Sample Collection
The drug suspension formulation, fluidized bed system and associated measurement were
described in chapter 2. The process was operated by the Simplex control (chapter 2) and monitored
by the robust NIR model built in chapter 3. A total of 21 drug layering batches were produced
using the Simplex control. Ten end product samples were withdrawn from each batch and analyzed
by UV method. The drug contents were converted to the percentage of label claim.
The procedures of sampling and UV analysis for the process capability measurement is
displayed in Figure 4.1. Ten batches produced using the hybrid control system were included for
the analysis. Ten replicates were randomly sampled from the end products and analyzed by UV.
A mean value (µ) and relative standard deviation (RSD) were calculated for each batch. The
process capability of batch repeatability was evaluated using the ten mean values, whereas the
RSD values were used to assess the batch homogeneity. Similar procedures of process capability
measurements were also performed for the basic control.
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Figure 4. 1 Procedures of sampling and UV analysis for assessing the process capability of the control systems.

4.2.2 Automation System
The automation system used in this chapter was similar to the one described in chapter 2
section 2.2.3. Figure 4.1 shows the updated structure of orchestrations in SynTQ. The NIR model
built in chapter 3 was implemented in the spraying phase and was highlighted in the orchestration.
The process endpoint was determined when the predicted drug contents reached the target.
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Figure 4. 2 Updated SynTQ orchestration implemented with the NIR model.

4.2.3 Design Space and DOE
The design space was developed by conducting experiments using a circumscribed central
composite DOE. The investigated factors were environmental equivalency factor (EEF) and
atomization pressure (AP). The calculation and interpretation of EEF were described in chapter 2.
It was used to describe the drying environment of a coating process (Ebey, 1987). Atomization
pressure, a factor involved in momentum transfer during coating, was investigated as the other
factor in the DOE. Table 4.1 lists the designed experiments. The center points of the DOE (batches
7, 10, and 11) had the EEF target of 0.64 and AP setpoint of 1.6 bar. The conditions were
discovered in chapter 2 from successful batches produced using basic control. The lower (0.55)
and upper (0.75) levels of EEF were chosen for two reasons. They were statistically different from
the center point (0.64) based on the calculation of confidence interval and were the maximum and
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minimum values without causing batch failures. The AP of 1.9 bar was the maximum setpoint
allowed by the equipment, and an AP value of 1.3 bar was selected to maintain a same difference
(0.3 bar) to the center point. All the 11 experiments were randomized to the ambient RH in a range
of 10.3% – 64.0%.
Table 4. 1 Circumscribed central composite DOE.

Batch #

EEF

AP (bar)

Ambient RH

1
2
3
4
5
6
7
8
9
10
11

0.55
0.64
0.75
0.75
0.55
0.64
0.64
0.75
0.55
0.64
0.64

1.9
1.3
1.6
1.3
1.6
1.9
1.6
1.9
1.3
1.6
1.6

23.5%
17.7%
64.0%
40.7%
50.0%
10.3%
62.1%
13.6%
23.9%
15.0%
53.3%

The responses of the investigated DOE were coating efficiency, content uniformity, and
agglomeration percentage. . Coating efficiency describes how much drug is actually layered on the
pellets comparing with the theoretically applied drug content. Itis a critical attribute for drug
layering process because the drug substances are normally very expensive. Reduced costs for
product development can benefit from an improvement in coating efficiency. Content uniformity
is a widely accepted CQAs for most pharmaceutical solid dosage forms. Agglomeration percentage
describes how much agglomerates formed at the end in the whole batch. It was perceived as an
important indication of batch yield, because any agglomerates will be removed from the end
products before proceeding to the next step.
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Coating efficiency and content uniformity were determined by the UV method established
in chapter 3 section 3.2.2. Coating efficiency was calculated as the ratio (w/w) of the layered drug
content to the theoretically applied (the amount of liquid applied multiplied by the nominal APAP
concentration). Content uniformity was expressed in relative standard deviation (RSD) of drug
contents by determining 10 replicates of the end products. Agglomeration percentage was
determined by a solid sizer (JM Canty Inc., NY). The pellets of the whole batch after coating, i.e.
end products, were scanned by a camera, while the pellets were in a consist motion controlled by
a shaker. The recorded video was subjected to image analysis, which was able to count the pellets
and pinpoint the agglomerates. An agglomerate was identified by meeting the criteria of having a
major diameter greater than 1.5 times larger than the average diameter of the whole batch pellets.
An example is shown in Figure 4.3, where the identified agglomerates are shown at the left, as
opposed to the individual pellets at the right. The agglomeration percentage was calculated by
dividing the sum area (black 2-D area in a binary image) of all the identified agglomerates by the
sum area of all objects captured in a complete scan. The scan was repeated three times, and the
average agglomeration percentage was used for subsequent analysis.

Figure 4. 3 Example of the measurement of agglomerates.
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An empirical model was calculated for each response using multiple linear regression. The
models were used to describe and understand the relations between the DOE factors and their
effects on the quality attributes. The relations were graphically portrayed in 3-D knowledge spaces
using JMP software (SAS, Cary, NC). A design space was established premising on the knowledge
space by setting the specification limits of each quality attribute: coating efficiency >= 55%,
content uniformity (RSD) <= 10%, and agglomeration percentage <= 15%. Note there was no
standard specification for the quality attributes of interest, therefore the specifications used to
develop design space had to be arbitrarily defined for the model system. The knowledge spaces
were combined and projected onto a 2-D contour plot. The setpoints of factors that can meet all
the defined specification limits constituted the design space. In this work each setpoint in the
design space referred to a combination of an EEF target value and an AP setting.

4.2.4 Operation Space
Design space is often an extrapolation of the response surfaces from a DOE. Hypothetically
the setpoint within the identified design space indicates a safe and successful operating condition.
Nevertheless, it requires supporting analysis to be sure operating in the design space will have high
success rates. Therefore, operation space, taking the variations of individual batch into account,
was used to discover the process setpoints that offer high probabilities of meeting specifications,
i.e. high confidence. It was used in this work to achieve process optimization. Operation space was
defined as a region situated in the design space, comprising the setpoints that can meet the
specification limits at a greater confidence. Unlike design space, it takes the variations from
individual batches into account. The operation space was established by adopting the procedures
of edge of failure analysis: (1) calculate response surfaces based on the results obtained from DOE,
(2) construct the design space, (3) simulate variations in each factor, (4) predict the responses using
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the response surfaces at the simulated variations, (5) calculate the probability of in specifications
for each setpoint in the design space, and (6) repeat step (3)-(5) for a large number of times. To
acquire reliable results, sufficient repetitions must be made. Monte-Carlo simulation with
repetition times of 5.0×103 was used as a default parameter in JMP software, and thus used as a
reference value in this work.

4.2.5Assessment of Process Capability
The goal of the hybrid control system was to improve process capability. The two CQAs
for assessing process capability were batch repeatability and batch homogeneity. The sampling
and drug content measurement for this study was described in 4.2.1. Process capability indices, 𝐶
and 𝐶 , were calculated by,
Eq. (4.1)

𝐶 =

𝐶

= min[

,

Eq. (4.2)

]

where 𝑈𝑆𝐿 and 𝐿𝑆𝐿 are desired upper and lower specification limits of the investigated CQAs, 𝜇
and 𝑠 are the mean and standard deviation measured in experiments. 𝐶 measures how close a
process is running to its specification limits, relative to the natural variability of the process. The
USL and LSL of batch repeatability were 115% and 85%, and 15% and 0% for batch homogeneity.
The specifications were chosen based on USP defined specifications.(USP, 2011)

4.3 Results and discussion
4.3.1 Design Space
The relations between the investigated factors and their effects on the quality attributes
were studied with a DOE. The knowledge spaces were constructed using the DOE results shown
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in Table 4.2. Figure 4.4 (A) shows the 3-D knowledge space plot of coating efficiency. The lowest
coating efficiency was produced at low level of EEF (0.55) and high level of AP (1.9 bar), whereas
the highest coating efficiency was at high level of EEF (0.75) and low level of AP (1.3 bar). In
general, higher AP produces smaller droplets with much greater specific surface area, enhancing
spray drying effect and decreasing coating efficiency. Its effect on coating efficiency was
exemplified by a higher drying rate (low EEF). On the contrary, lower drying rate and larger
droplet size maximized the coating efficiency, possibly by inhibiting the effect of spray drying. It
is noteworthy that the plot reveals an interaction between EEF and AP. The AP had little impact
on coating efficiency when the EEF was held at low level. It was inferred that extremely excessive
drying rate was produced at EEF of 0.55. This resulted in significant spray drying, regardless of
the level of AP was used. In contrast, AP had significant impact on determining coating efficiency
when EEF was at high level (0.75). The coating efficiency was nearly doubled by decreasing AP
from 1.9 bar to 1.3 bar. The result of lower coating efficiency at high AP implied that the spraying
drying seemingly dictated the coating efficiency, even at lower drying rate. The greatly enlarged
specific surface area make the coating droplets extremely susceptible to spray drying. This may be
relevant to the high solid concentration (17.5%) of the drug suspension.
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Table 4. 2 Results of the DOE for establishing design space.

Run #

EEF

AP (bar)

RH%

1
2
3
4
5
6
7
8
9
10
11

0.55
0.64
0.75
0.75
0.55
0.64
0.64
0.75
0.55
0.64
0.64

1.90
1.30
1.60
1.30
1.60
1.90
1.60
1.90
1.30
1.60
1.60

24.00%
18.00%
64.00%
41.00%
50.00%
10.00%
62.00%
14.00%
24.00%
15.00%
53.00%

Coating
efficiency (%)
46.30%
93.70%
74.20%
94.60%
48.10%
52.60%
57.40%
60.80%
46.60%
49.70%
48.90%

Agglomeration
percentage (%)
3.60%
17.80%
9.50%
32.00%
6.80%
7.20%
9.50%
7.10%
26.80%
13.00%
11.40%

Content uniformity
RSD (%)
4.20%
9.10%
15.90%
16.30%
2.30%
7.70%
1.80%
4.90%
7.20%
2.80%
6.90%

Similar effects of AP and EEF on content uniformity are observed in Figure 4.4 (B). content
uniformity was represented by RSD, and therefore a high RSD value represented a poor content
uniformity. A lower RSD was obtained at low EEF, regardless of the level of AP. AP had little
impact on RSD when the EEF was kept low, but an extraordinarily increased influence on RSD
was found when EEF was held at high level. The similarity of the knowledge spaces of coating
efficiency and content uniformity was explained by their relationships. A greater coating efficiency
was often accompanied by a higher RSD (poor content uniformity). High coating efficiency is
obtained by inhibiting spray drying, which can be achieved by lowering drying rate (higher EEF)
and decreasing AP. However, this significantly enhances the risks of forming agglomerates. Liquid
bridges are easily formed when the over-wetting pellets collide with each other. Therefore, high
coating efficiency and low RSD are considered conflicting results. This was corroborated by the
results of batches 2 and 4 in Table 4.2, both had high coating efficiency with high RSD. Although
higher coating efficiency is always desired, over pursuing it can compromise content uniformity
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and may even lead to batch failure. Considering the severe consequence of batch failure, a tradeoff criterion prone to a lower RSD was used in this work.

Figure 4.4 Knowledge spaces. A: Coating efficiency; B: Content uniformity (expressed in RSD); C: Agglomeration
percentage.
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It was intuitive to presume a similar relationship should hold between content uniformity
and agglomeration percentage, because a lower RSD usually resulted from inhibited formation of
agglomerates. However, Figure 4.4 (C) reveals the agglomeration percentage was determined by
AP, whereas EEF had insignificant effect. The discrepancy of the results between content
uniformity and agglomeration percentage was conceivably related to difference in measurement.
The content uniformity was determined by the UV method. A poor content uniformity indicated
large chunks of agglomerates were formed during the process, because the large agglomerates
(with a minimum size of 2.38 mm) usually contain much more drug than individual pellets. The
small agglomerates had little impact on content uniformity, because hundreds of pellets constituted
a single sample which was analyzed by UV. In general, the large agglomerates were produced by
insufficient drying rate. This explained the significant effect exerted from EEF on content
uniformity. On the other hand, agglomeration percentage was determined by image analysis. The
image analysis was able to capture all the pellets. Therefore, the small agglomerates had a
remarkable influence on the AG. Figure 4.4 (C) shows the lower AP had adverse effects on
agglomeration percentage, which was independent of the EEF levels. The properties of larger
droplets with lower impingement speed may result in a thick wet surface on the pellet, encouraging
the formation of liquid bridges and thereafter creating more agglomerates. Because the high
viscosity of the drug suspension, even the highest drying rate used in this work was insufficient to
inhibit the wet surface.
The design space was obtained by combining the knowledge spaces and identify the
setpoints of in specifications. In Figure 4.5, each colored area represents where the setpoints fail
to meet the specification limits. The white area in the middle is the discovered design space.
Hypothetically, operating the process using any setpoints in the design space is able to meet the
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specifications. However, simply using the design space is misleading because it only represents
the average of the quality attributes predicted by the response surface. A regular design space
disregard the variations from individual batches. The mean response may be safe, but the
individual batch may experience high failure rates. The dashed lines in the plot are boundaries of
the design space, which were reckoned as edges of failure.(Little, 2014) If the setpoints are
randomly and normally distributed, 50% of the batches produced at the boundaries will fail to meet
the specifications.

Figure 4. 5 Design space of the drug layering process.

4.3.2 Operation Space
The effect of repetition times on the operation space was examined. Figure 4.6 from (A) to
(C) display the operation space obtained by repeating the Monte-Carlo simulation 1.0×10 4,
5.0×104, and 1.0×105 times, respectively. The SD of EEF and AP were held constant in the
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comparison. No distinguishable difference was found among the three plots, suggesting repetition
of 1.0×104 times was sufficient for conducting the EFA. The red region represents where the
setpoints have higher probability to meet the specifications. The exact boundaries of an operation
space are defined for a specific process, based on the desired confidence level.

Figure 4. 6 Effect of the number of repetitions on the operation space.

The variation of the EEF was revealed having a significant impact on the size of the
operation space. Figure 4.7 shows the results of two examples. The SD of AP was held constant
in the examples for demonstration. A much larger red region (Figure 4.7 (A)) was obtained by
setting the SD of EEF at 0.02, the results indicated many setpoints in the design space can meet
the specifications at high confidence level. In contrary, Figure 4.7 (B) exhibits when the SD of
EEF is set at 0.08, none of the setpoints can meet the specifications with a confidence higher than
70%. Since AP had very limited range and variation (mainly resulted from the random variance of
the air supply), its effect on the operation space was insignificant compared with the effect of the
EEF.
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Figure 4. 7 Effect of the standard deviation of EEF on the operation space.

The optimized process setting was found in the operation space by finding the setpoint
having the maximum probability of in specifications. Figure 4.8 shows the operation space
established based on the experimentally determined SD of EEF (0.05) and a best estimated SD of
AP (0.05). The optimized process setting, symbolized by the white diamond at EEF = 0.72 and AP
= 1.80, give the highest confidence at a value of 86.35%. The original setpoints, indicated by the
white circle, produced a 68.04% confidence of in specifications. The optimized process setpoints
were used in subsequent experiments to test the process capability.
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Figure 4. 8 Process optimization. White circle: original setpoints; White diamond: optimized setpoints.

Table 4. 3 Comparison of the probability of in specifications. Before and after process optimization.

Process optimization

EEF
mean

EEF
SD

AP
mean

AP SD

Probability of in
specifications

Preliminary process
setpoints

0.64

0.05

1.60

0.050

68.04%

Optimized process setpoints

0.72

0.05

1.80

0.050

86.35%
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4.3.3 Assessment of Process Capability
The results of process capability were calculated for both hybrid control and basic control.
The results of basic control are discussed at first. Figure 4.9 (A) displays the X-charts of batch
repeatability. Each point in the plot is a mean drug content measured by UV for each batch. The
horizontal axis shows the sorted ambient RH used for the batch productions. The green solid line
is the mean drug label claim of all 10 batches, which is 100.5%. The two red lines, UCL and LCL,
are confidence intervals calculated from the mean and SD. The blue dashed lines are USL (115%)
and LSL (85%) based on USP specifications. An outlier at RH of 77% was highlighted in the red
dashed circle in the figure, which had extraordinarily greater RSD than other batches (discussed
in subsequent section), and therefore was not included in the calculation of process capability
indices. Figure 4.9 (B) shows the simulated distribution based on the measured mean and SD for
the batch repeatability. Only 46.06% of the population falls within the USL and LSL. The value
corresponds to a failure rate of 5.39×105 parts per million (PPM). Although the overall mean drug
label claim was very close to the center target (100%), the process had extremely poor capability
for batch repeatability, as evidenced by the capability indices of 𝐶 = 0.21 and 𝐶

= 0.20. The

low indices were attributed to the poor precision of between-batch drug contents. The basic control
determined the process endpoint by applying a fixed amount of coating liquid. This method
ignored the variation in coating efficiency, which was proved rather evident in Table 4.2.
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Figure 4. 9 Process capability of batch repeatability under basic control. A: X-charts of batch repeatability; B:
Simulated distribution of the batch repeatability population.

The results of batch homogeneity are shown in similar plots (Figure 4.10), where USL of
15% (blue dashed line) was used as specification limits, note the LSL is zero. The outlier, RSD of
74.9% at RH of 77%, is highlighted in red dashed circle in Figure 4.10 (A). Also, a RH-dependent
pattern is seen in the plot: higher RH resulted in higher RSD (comparing the range above 50%
with that of lower than 22%). The results pointed out a special cause variance existed in the process
produced by basic control. Due to its extraordinary leverage on the calculation, the outlier batch
was excluded in the calculation of process capability indices. Figure 4.10 (B) shows 93.13% of the
population falls in the specifications (failure rate of 686.51 PPM). The batch homogeneity had 𝐶
= 1.13 and 𝐶

= 1.11. The indices suggested the batch homogeneity of the drug layering process

was marginally capable.

94

Figure 4. 10 Process capability of batch homogeneity under basic control. A: X-charts of batch homogeneity; B:
Simulated distribution of the batch homogeneity population.

Substantial improvements offered by hybrid control, particularly for batch repeatability,
are demonstrated in Figure 4.11. Figure 4.11 (A) shows a much enhanced precision as all the drug
content are well confined to the USL and LSL. The 𝐶 and 𝐶

of batch repeatability were

increased up to 1.11 and 1.10, respectively. The failure rate was decreased considerably to a PPM
value of 898.6, representing 99.97% of the population was in specifications. The significantly
reduced variation in drug label claim was attributed to the endpoint determined by the process
monitoring system. The NIR model provided accurate predictions of the drug layered content,
effectively inhibiting the batch to batch variation. The batch homogeneity was also improved by
the hybrid control. The random patterns in Figure 4.11 (C) indicates the special cause variance
associated with RH was successfully removed. The RSD of each batch was effectively controlled
at similar level and independent of the change in ambient RH. The 𝐶 and 𝐶
2.12 and 1.62. Note, the lower 𝐶

were increased to

is explained by Figure 4.11 (D), where the average RSD is

closer to the lower limit. This, in fact, indicated a higher capability for batch homogeneity. Overall,
the hybrid process control system had significantly improved the process capability for the drug
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layering process. The process capability of batch repeatability was enhanced from extremely poor
to marginally capable, whereas excellent process capability was achieved for the batch
homogeneity than the previous marginally capable process. The significance was substantiated by
statistical evidence (α=0.05) of the capability indices (Table 4.4). A process having 𝐶

>= 1.33 is

usually acknowledged as a capable process given the widely accepted industrial standard.
Therefore, the hybrid process control has not yet achieved “capable control” for batch repeatability
(𝐶

= 1.10). It is noteworthy that the capability indices reported in the industry is usually based

on the measurements of numerous subgroups from the production line. The less data included in
our calculation may underestimate the process capability. Nevertheless, the hybrid control proved
its effectiveness of improving process capability compared to the basic control.
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Figure 4. 11 Process capability of batch repeatability and homogeneity under hybrid control. A: X-charts of batch
repeatability; B: Simulated distribution of the batch repeatability population; C: X-charts of batch homogeneity; D:
Simulated distribution of the batch homogeneity population.

Table 4. 4 Comparison of the capability indices between basic and hybrid controls.

Control mode
Basic control （outlier removed)
Hybrid control

Process capability
Batch repeatability
Batch homogeneity
𝐶
𝐶
𝐶
𝐶
0.21

0.20

1.13

1.11

1.11 *

1.10 *

2.12 *

1.62 *

*: significant difference at confidence level α=0.05
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4.4 Conclusion
Process optimization was efficiently achieved by employing the operation space in this
work. The effects of the process factors on the quality attributes of interest were investigated using
DOE. Besides EEF, factor affecting the momentum transfers at microscopic level (AP) also had
significant influences on the quality attributes (coating efficiency, content uniformity and
agglomeration percentage in this work). The results suggested the factors having complex effects
at microscopic level should not be ignored. The subtle interaction phenomena was practically
difficult to control, therefore it was regarded as a supplementary factor in this work to achieve
process optimization.
The size of the operation space was determined by the specified confidence level. Besides,
the variation of EEF also had significant effect on the operation space. A lower variation of EEF
produced a larger operation space, endowing more flexibility in choosing process setpoints. AP
did not show any noticeable impact on the operation space, which was inferred due to its limited
variability.
The operation space discovered the optimum setpoints, which were EEF of 0.72 and AP of
1.8 bar. The expected probability of in specifications was increased, by estimation, from 68.04%
to 86.35%. By consolidating nine process parameters into a single value, the use of EEF
considerably reduced the number of experiments required for the process optimization. Therefore,
the use of operation space with EEF allowed efficient process optimization.
The works in this chapter, combining with chapter 2 and 3, completed the proposed hybrid
process control system. The process capability indices were calculated and compared with the
basic control. The results indicated the hybrid control system considerably improved the process
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capability indices. The 𝐶 and 𝐶

of batch repeatability were raised to 1.06 and 1.04, which were

approximately six times larger than the basic control. The indices of batch homogeneity had
twofold increase than the basic control, supported by the 𝐶 of 1.50 and 𝐶

of 1.14. The

improvement was substantiated by statistical evidence at significant levels α of 0.01 and 0.05,
respectively. The results supported the central hypothesis of the dissertation: The hybrid control
system improved the process capability for the drug layering process compared to the conventional
basic control.
The proposed control strategy was expected to have broader applications. The three
elements of the demonstrated hybrid control system: process manipulation, monitoring, and
optimization are adjustable and flexible. Pellet coatings are also commonly used to provide other
functions, such as core protection and drug release modification. In these applications, the
challenges are to ensure the quality to achieve the intended functions. Therefore, the next two
chapters of the dissertation focuses on exploring alternative analytical methods to monitor different
CQAs. With a successful development of alternative process monitoring method, the hybrid
control system can be updated and applied to various processes.
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Chapter 5: Develop Process Monitoring Method for Quantitative
Analysis of Coating Thickness
5.1 Introduction
A hybrid process control system was successfully developed in Chapter 2-4 for a drug
layering process. The system manipulated the coating process using the Simplex control. The
process endpoint was automatically determined using a robust NIR model. The optimum process
setpoints were discovered by an established operation space. The hybrid control succeeded in
improving the process capability for the investigated drug layering process. The proposed control
strategy was expected to have a broader applications. The elements of the demonstrated hybrid
control system, process manipulation, monitoring, and optimization, are adaptable and flexible.
By replacing one or several elements, e.g., process monitoring of a different CQA by alternative
analytical methods, the hybrid control system can be updated and applied to various processes.
Besides drug layering, fluidized bed pellet coating process is also commonly used for
achieving core protection and drug release modification (Bley et al., 2009; Tønnesen, 2001). In
these applications, coating thickness is often considered a CQA, which is strictly controlled to
ensure the product quality. A sufficient coating thickness can effectively reduce light penetration
(Bechard et al., 1992) and inhibit moisture diffusion(Bley et al., 2009). Coating thickness also
plays an important role in determining drug release properties (Siepmann et al., 2007; Wesseling
and Bodmeier, 1999b). In general, it is easier to control the coating thickness instead of changing
the formulation. In previous studies, NIR and Raman spectroscopy presented significant spectral
changes correlating with the coating process. The increase of coating thickness is, fundamentally,
a result of the deposition of coating materials. Because the sensitivity to chemical attributes, it was
presumed NIR and Raman are able to develop quantitative analysis of coating thickness.
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A drawback of using NIR or Raman spectroscopy is the requirement of calibration. As
indirect methods, the spectra must be related to the reference values to build empirical models.
The most reliable reference methods for determining coating thickness are normally image
analyses using optical or electron microscope. However, the methods are destructive and often
require significant time for sample preparation and data collection. Although the advantages
offered by a successful NIR or Raman method considerably outweighs the efforts for building the
empirical models, the endeavor of method development should not be omitted.
An analytical method that can provide direct, non-destructive, and rapid measurement is
preferred for determining coating thickness. Terahertz imaging (THI) has demonstrated the
potential to determine tablet coating thickness (Cogdill, 2006; Fitzgerald et al., 2005; Ho et al.,
2009b; Maurer and Leuenberger, 2009). Terahertz radiation is in the far-infrared region of the
electromagnetic spectrum (60 GHz–4 THz). The low frequency radiation allows high penetration
depth in solid samples (Haaser et al., 2013a). Unlike NIR and Raman spectroscopy, THI offers
direct measurements of coating thickness without the need for developing calibration models.
These advantages make THI a valuable tool to determine the coating process.
However, THI was reported to have a high detection limit of 30–40 µm (Brock et al., 2012).
This shortcoming substantially limits its application to determine coating thickness. Therefore, the
indirect methods using NIR and Raman spectroscopy were included in the work of this chapter for
comparison. The goals of this study were to: (1) develop empirical models of coating thickness
using NIR and Raman spectroscopy, and (2) inspect the capability of THI to provide direct
measurement of pellet coating thickness.
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5.2 Materials and methods
5.2.1 Formulation of polymer coated pellets
The formulation of the polymer dispersion is listed in Table 5.1. Pellets (SUGLETS,
Colorcon, West Point, PA) were used as cores for the polymer coating process. The pellets have a
diameter range of 1000-1200 μm. Talc (Alfa Aesar, Haverhill, MA) and Tween 80 (VWR, Radnor,
PA) were added to the HPMC (PharmaCoat 606, Shin-Etsu, Japan) solution prepared beforehand.
The dispersion was mixed for 15 minutes. After the addition of Eudragit aqueous dispersion
(NE30D, Evonik, Germany) and pigment, the dispersion were further stirred for another 15
minutes. The mixed dispersion was diluted using deionized water to reach the desired polymer
solid concentration, and passed through a 0.5 mm sieve before used for coating.
Table 5. 1 Formulation of Eudragit polymer dispersion.

Polymer dispersion
Components
Concentration (%)
Eudragit NE 30D
9.00%
HPMC
1.00%
Tween 80
1.00%
Talc
10.00%
Pigment
0.50%
Deionized water
78.50%

5.2.2 Fluidized Bed Process, Sample Information, and Spectroscopic Data Collection
Three batches of Eudragit coating were performed by operating the process at the settings
shown in Table 5.2. The basic control was used to manipulate the process because all of the three
batches were produced at similar ambient conditions. Samples were taken from the process using
a built-in sample thieve, at predetermined coating time during the spraying phase. Two batches
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were used for calibration, and one batch for test. The coating process was monitored by the in-line
NIR spectroscopy. The details of NIR spectra collection were described in chapter 2 section 2.2.2.
Raman spectra were collected using a RXN2 Hybrid at-line analyzer (Kaiser Optical
Systems, Ann Arbor, MI) with a thermoelectrically cooled charge-coupled detector. The laser
source was operated at 785 nm with a laser power of 400 mW. The spectrometer was equipped
with a non-contact optic sampling device PhAT probe. The focal length was 250 mm and spot size
was 6 mm. The coated pellets were held in a sample holder with a depth of 10 mm and a diameter
of 8 mm. The sample holder was positioned perpendicular to the PhAT probe. The exposure time
was set as 20 s, and each sample was scanned three times over the wavenumber range of 150-1890
cm-1 at a 1 cm-1 increment. The final spectrum was a co-add of the three scans.
Table 5. 2 Process settings of polymer coating produced using basic control.

Process setpoints
3

AF (m /h)
IT (˚C)
SR (g/min)
AP (bar)

Preheating
40
55
0
0

Phase
Spraying
Drying
50
40
50
65
5
0
1.6
0

Cooling
35
21
0
0

5.2.3 Reference Method: Image Analysis
Image analysis was used as a reference method to determine the pellet coating thickness.
Ten pellets were randomly selected from the samples taken from the process. Each pellet was
cross-sectioned using a Microtome (Thermo Scientific, Boston, MA). The image of the crosssectioned pellet was taken using an optical microscope and saved in RGB format (Olympus, Japan).
Each image had 1920×2560 pixels, with pixel size of 0.836×0.836 μm. An in-house function
written in MatLab was applied to make numerous thickness measurements on each image. An
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image of the cross-sectioned surface is presented in Figure 5.1 (A). The coating surface is
highlighted in green circles and the interface of the coating and core is indicated by red circles. A
thickness distribution was obtained for each pellet. The standard deviation (SD) was calculated to
indicate the intra-pellet thickness variation. An example of the distribution is shown in Figure 5.1
(B). The pooled mean (µ) and SD were calculated from the thickness data of the 10 pellets. The
mean thickness of each sample was used as reference value for developing empirical models.

Figure 5. 1 Image analysis of pellet coating thickness using optical microscope. A: Cross-sectioned surface of pellet
and coating layer identified; B: Intra-pellet thickness distribution.

5.2.4 Indirect Method: Empirical Models using NIR and Raman Spectroscopy
NIR and Raman models were built by relating the to the reference values. The model
development protocols were described in chapter 3 section 3.2.4 and section 3.2.4.3. In this case,
the reference values were the mean coating thickness values of the samples determined by optical
microscope.

5.2.5 Direct method: Terahertz imaging
A total of six samples with different weight gains were selected for the THI analysis. Eight
replicate pellets of each sample were fixed in a holder and subsequently imaged individually using
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a THI in reflectance mode (TAS7500IM, Advantest, San Jose, CA). The terahertz incident beam
was manually focused on the highest point of the pellet surface by moving the position of the
sample holder in a 3-D coordinate system. The spatial resolution of the images was set to 0.1 mm.
A single time domain waveform was collected by averaging 128 replicate scans for each pellet.
The measurements were repeated six times and thus six terahertz waveforms were obtained for
each pellet. The mechanism of THI measurement is graphically illustrated in Figure 5.2. The
following equation was used to directly derive the coating thickness from the terahertz waveform,
𝑑=

∙∆

Eq. (5.1)

∙

Here 𝑑 is coating thickness measured by THI, 𝑐 is the speed of light in air. ∆𝑡 is the time difference
between the reflection of the terahertz pulse off the coating surface (r1) and the reflection from the
interface of the coating and core pellet (r2). 𝑛1 is the RI of the coating material. The refractive
index (RI) used to calculate the coating thickness was determined by scanning a coating film patch
using the THI transmission mode. The film patch was prepared by casting the same coating
dispersion on a Teflon petri dish. The film was dried in an oven at 60°C for 24 hours before
scanning. The RI used for thickness calculation was the average of the spectra RI over the
bandwidth of the THI system (1-4 THz). A stainless steel sphere with diameter of 1.59 mm was
used to acquire a reference surface reflection.
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Figure 5. 2 Terahertz imaging measurement

5.3 Results and discussion
5.3.1 Image Analysis using Optical Microscope
The image analysis used in this work allowed numerous measurements of thickness made
on each pellet. The number of measurements is of great importance to acquire a statistically
representative average thickness. Its effect is illustrated in Figure 5.3. The subplots from (A) to (D)
present the histograms of thickness data obtained from 6, 36, 72, and 360 measurements,
respectively. Increasing the number of the measurements caused a change in average thickness
from 52 to 59 µm. Meanwhile the distributions of the thickness gradually conformed to a normal
distribution. In this work, 360 thickness measurements were made on each individual pellet. The
mean (µ) and SD were calculated from a total of 3600 thickness measurements. In Figure 5.4, the
average thickness values are indicated by the open circles, while the SD values are shown as the
spread at each time point. The near linear relation of the thickness versus coating time was due to
the limited range of the coating thickness investigated in the work.
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Figure 5. 3 Effect of the number of thickness measurements on the coating thickness distribution.

107

Figure 5. 4 Increase of coating thickness versus coating time.

5.3.2 NIR model
The most evident feature of the raw NIR spectra is the baseline variation, as shown in
Figure 5.5 (A). The baseline variation was mainly associated with the fluidization. A principle
component analysis (PCA) model was built by preprocessing the NIR spectra of a calibration batch
using SNV and mean-centering. The distribution of the scores on PC1 and PC2 are displayed in
Figure 5.5 (B). A clear pattern of the PC scores is seen in the plot, where the dark blue circles
indicate the beginning of the coating, and yellow circles represent the end of the spraying. The
PC1 explained 84.45% of the spectra variance, which was attributed to the increase of coating
thickness, whereas the PC2 captured 8.04% spectra variance, which was presumably associated
with the variation in water content.
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Figure 5. 5 Qualitative analysis of NIR. A: Raw in-line NIR spectra during coating; B: PCA score plot of the NIR
spectra.

Quantitative NIR models were calculated using the spectra of two calibration batches and
the reference values provided by the image analysis. The NIR spectra were preprocessed by SNV
and followed by mean-centering to emphasize the spectra features of the absorbance. The
predictions of the NIR model versus measurements are presented in Figure 5.6 (A). The optimized
NIR model gave RMSEC of 3.53% and RMSEP of 3.40% (normalized to the calibration range).
Figure 5.6 (B) shows the two latent variables (LV) overlaid with the pure spectra of core pellet
and coating film. The two LVs both resemble the spectra features of the coating film, as evident
from the weights in the regions of 1390 nm and 1670-1750 nm.
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Figure 5. 6 Model performance of the thickness model built using NIR. A: Predictions of thickness versus
measurements; B: Latent variables (LV) overlaid with pure spectra of core pellet and coating film.

A main advantage offered by the image analysis used in this work was the availability of a
large data set of thickness measurements. This allowed one to inspect the uncertainty of the coating
thickness and its effect on the model performance. Figure 5.7 elucidates the steps of the analysis
using bootstrapping. A thickness probability distribution was created for each sample at a different
coating thickness. A normal distribution was simulated using the determined µ and SD acquired
from the image analysis. Thickness values were randomly drawn from the distribution and used as
reference values to build new NIR calibration models. The calibration error (RMSEC) of the
simulated models were compared with the original model established using the average thickness
data. The analysis was repeated k times (1×104 in this study), and therefore k models and associated
RMSEC were calculated.
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Figure 5. 7 Illustration of bootstrapping analysis.

The variability of the thickness was found independent of the average coating thickness, as
evident from the random pattern shown in Figure 5.8 (A). The results of the bootstrapping analysis
is shown in Figure 5.8 (B). The RMSEC of the original model (4.37 µm) is represented by the red
line, whereas simulated RMSEC were represented by the blue histogram. The RMSEC of the
original model was lower than 96.34% of the simulated models. The results indicated using the
average thickness data was reasonable to build NIR model.
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Figure 5. 8 Effect of the thickness variability on NIR model development. A: Pooled standard deviation versus the
mean of the coating thickness; B: RMSEC of simulated NIR models (blue histogram) and the original model (red
line).

5.3.3 Raman model
The raw Raman spectra of core and coated pellets are shown in Figure 5.9 (A). The Raman
spectra of coated pellets reveal a baseline drift which is proportional to the coating thickness. The
drift was associated with the components, talc and HPMC. These two components had much
stronger Raman signal than the Eudragit polymer. They were also characterized by the
considerable baseline slopes, which dominated the observed Raman spectra of coated pellets. To
remove the baseline interference, the Raman spectra were preprocessed using baseline correction.
The preprocessed spectra are shown in Figure 5.9 (B). Remarkably decreased intensity is seen in
the regions characteristic of the core pellet, especially in 1000-1200 cm -1. However, the spectra
changes were hardly distinguishable between the thickness of 72.23 µm and 99.25 µm.
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Figure 5. 9 Raman spectra of coated pellets. A: Raw spectra; B: Baseline corrected spectra.

A preliminary Raman model was built in the coating thickness range of 24.82-99.50 µm.
Figure 5.10 shows the model predictions versus reference measurements. A slight non-linear trend
is found near the higher end of the thickness range. The model gave a RMSEC of 9.77% (relative
to the calibration range). The results suggested Raman method may not be suitable for analyzing
samples with high coating thickness. It was important to have the knowledge of the maximum
coating thickness beforehand. If the coating thickness of interest is above the limit, alternative
methods should be explored.
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Figure 5. 10 Preliminary Raman model in thickness range of 24.82-99.50 µm.

The concept of information depth (ID) was proposed to estimate the maximum thickness
range that allows development of a quantitative Raman model. The ID was defined as the
maximum depth in a solid sample to which an incident radiation wave can penetrate, meanwhile
still allowing sufficient photons backscatter for detection by the spectrometer. ID is graphically
illustrated in Figure 5.11. Before coating starts, the spectra only contain chemical information of
the core pellet (Figure 5.11 (A)). With the increase of the coating thickness, (Figure 5.11 (B) and
(C)), the chemical information of the spectra gradually emphasize on the coating layer. The spectra
change eventually becomes imperceptible when the thickness exceeds the maximum limit, as is
shown in Figure 5.11 (D). Therefore, ID is conceptually indicated by Figure 5.11 (C). A sufficient
spectra change is a precondition for building empirical models using any spectroscopic methods,
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therefore ID determines the maximum range of thickness allowed for developing a quantitative
model.

Figure 5. 11 Illustration of the information depth.

The high selectivity of Raman spectroscopy allows one to use the distinct spectral features
of each component to quickly estimate the ID. The baseline corrected Raman spectra of pure core
pellet (red) and coating (blue) are shown in Figure 5.12. The ideal spectra features for probing the
ID should have distinct signal and minimum interference from other components. Given this
requirement, the intensity at 1728 cm-1 and 943 cm-1 were used to indicate the spectral changes of
the coating and the core, respectively. Figure 5.13 (A) shows the intensity at 1728 cm -1 is
proportional to the coating thickness. However, an inflection point indicated by the change from
near-linear increase to a plateau was observed at a thickness value of 72.23 µm. A similar result
was also found at 943 cm-1 in Figure 5.13 (B). Therefore, the ID was approximately deduced at a
thickness of 72 µm. Note, ID is affected by coating formulations and instrumental settings. Light
penetration is considerably blocked by the opacifiers in the coating layer. The penetration is also
dependent on the wavelength and power of the laser source. Therefore, the ID in this work is an
empirical parameter defined for the specific sample.
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Figure 5. 12 Pure Raman spectra of core pellet (red) and coating film (blue).

Figure 5. 13 Analysis of information depth. A: Change of Raman intensity at 1728 cm-1; B: Change of Raman intensity
at 943 cm-1.
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A Raman thickness model was developed within the discovered ID. The optimized Raman
model was built by preprocessing the spectra using baseline correction, Savitzky-Golay 1st
Derivative and mean-centering. The model gave a RMSEC of 4.91% and RMSEP of 2.98%,
considerably outperformed the preliminary model built in a broader thickness range (RMSEC of
9.72%).
The significant difference in the thickness ranges of NIR and Raman models may be
explained by their inherent characteristics. NIR spectroscopy is sensitive to both chemical and
physical attributes of in-process materials. The increase of coating thickness naturally results in
increasing particle size, of which has effects on baseline, absorption and scattering (Ciurczak et
al., 1986; Ely et al., 2008). The effects of particle size on spectra, and the correlation of particle
size and coating thickness lead to a greater covariance captured by the NIR model. This helps the
model to predict the coating thickness at higher levels. On the other hand, Raman spectroscopy is
less sensitive to the change in the physical attributes, and thus the prediction range is highly
contingent on the information depth.

5.3.4 Terahertz image (THI) analysis
The amplitude of a terahertz waveform is proportional to the RI difference between two
adjacent medium. The raw terahertz waveforms of the reference (red) and coated sample (blue)
are displayed in Figure 5.14 (A). The amplitude of the surface reflection of the sample is much
weaker than the reference. The RI of the reference material, stainless steel, is of 2.76 (Filmetricts).
It is much higher than the RIs of commonly used pharmaceutical materials which are usually in
the range of 1.3 – 1.7 (May et al., 2011). The slight shift of the peak in the sample spectrum relative
to the reference was due to the difference in their diameters. The diameters of the coated samples
were usually 0.2 mm less than the reference (1.59 mm). The diameters determined the travel
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distance of the terahertz pulse (from pulse generator to sample surface and back to detector). The
smaller the sample, the longer distance terahertz pulse needed to travel. Figure 5.14 (B) shows the
RI measurement in a frequency domain plot. The measurements were made by scanning both sides
of the film patches made of the same coating formulation. The RIs were similar in the frequency
range of 1-4 THz, therefore an average value of 1.72 was used to calculate the coating thickness.

Figure 5. 14 Terahertz image analysis. A: Terahertz time domain waveform; B: Refractive index measurement.

The sample waveforms were normalized to the reference in both amplitudes and time scales.
Figure 5.15 (A) shows an example, in which the sample waveform (green) is normalized to the
reference (red). The second reflection signal, represented as the smaller peak in the sample after
the first and strongest surface reflectance peak, is an indication of the interface of coating and core
pellet. The time delay was obtained by averaging the estimations from six waveforms collected
for each pellet. The coating thickness was subsequently calculated using Eq. 5.1. The results of
the THI measurements were compared with the reference provided by optical microscope. Figure
5.15 (B) shows a non-linear pattern near the lower end of the thickness. An average thickness value
of 48.85 µm was provided by THI, as opposed to 37.82 µm measured by the optical microscope.
The results of samples with larger thickness were similar between two techniques.
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Figure 5. 15 Terahertz image analysis. A:Normalized terahertz waveforms; B: Coating thickness comparison: terahertz
imaging versus optical microscopy.

It was conjectured that measurement of THI reached the detection limit near 50 µm. Close
to this limit, it was difficult to resolve the reflectance of the coating/core interface from the
reflectance of the surface. The observed detection limit was higher than the one reported in
literature (30-40 µm) for tablet coating (Haaser et al., 2013a). The terahertz pulse propagating in
a direction normal to the sample surface produces the highest reflectance intensity, which
theoretically provides most accurate measurement. Due to the size and spherical nature of the
pellets, and the manual experimental setup, the pellet curvature may lead to considerable terahertz
radiation scattered away from the detector, resulting in significant signal loss. A decrease in the
amplitude of the reflectance pulse is associated with an increased difficulty in resolving the second
reflectance. Unlike the established empirical models, THI provided a direct measurement of the
coating thickness. Also, THI performed better for samples with higher coating thickness, whereas
the thickness ranges of NIR and Raman models were limited by the ID. Therefore, THI was
perceived as a promising analytical method complementary to the empirical modeling approaches.
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5.4 Conclusion
Coating thickness is a well acknowledged CQA that should be strictly controlled for a
functional pellet coating process. This study investigated two approaches for quantitative analysis
of pellet coating thickness. Empirical models of NIR and Raman spectroscopy were developed as
indirect methods to determine coating thickness, whereas THI was employed to provide direct
coating thickness measurements.
The customized image analysis using optical microscope offered more representative
thickness data for empirical model development. The effect of the variation of thickness on the
NIR model development was probed using bootstrapping simulation. The calibration error
(RMSEC) of the ordinary model was smaller than 96.34% of the simulated models. The results
justified the use of average thickness as the model responses. The optimized NIR model gave a
RMSEC of 3.53% and RMSEP of 3.40%. All the errors were normalized to the range of the
calibration (20.1-123.65 µm).
Non-linearity was found in the Raman model built in the thickness range of 24.82-99.25
µm. The information depth was examined by tracking the spectral changes in the course of increase
in thickness. Limited spectral change was observed when the coating thickness exceeded 72.23
µm. Therefore, the information depth was estimated near this thickness value. By limiting the
thickness range of 24.82-72.23 µm, a Raman model built had considerably lower calibration error
(4.91%) than the original model in the range of 24.82-99.25 µm (9.77%). Although the range of
Raman model was narrower than the NIR method, it still covered a sufficient range used in routine
pharmaceutical coating process.
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Terahertz imaging was investigated as an alternative technique that may offer direct, nondestructive, and efficient estimation of pellet coating thickness. The thickness determinations
provided by THI were similar to the optical microscope in the range of reference thickness greater
than 50 µm. However, significant discrepancy of the results was found below this thickness level.
The estimated detection limit of THI was at about 50 µm, higher than the one reported in literature
(30-40 µm). The difference may be explained by the weak terahertz signal associated with the size
and spherical shape of the samples.
The empirical model of NIR had a broader range of coating thickness, and lower RMSEC
(3.53%) and RMSEP (3.40%). However, the concern was that the broader thickness range was
obtained by capturing correlated variance other than coating thickness, complicating the model
interpretation. Although the Raman model had a narrower thickness range, its superior selectivity
indicates the model is more selective to the coating thickness, and easier for data interpretation.
Also, the greater selectivity allows a quick estimation of the information depth, which enables an
efficient decision making for technique selection. If the thickness of interest exceeds the
information depth, alternative techniques should be explored. Terahertz imaging does not require
empirical modeling, it offers direct, rapid, and non-destructive thickness measurement. It provided
more accurate measurement at a greater thickness level. But its shortcoming is the higher detection
limit, restricting its use to measure samples with smaller coating thickness. Despite each technique
has its own drawbacks, with their demonstrated strengths, NIR, Raman, and THI were considered
as complementary tools that are valuable for developing quantitative analysis of coating thickness.
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Chapter 6: Develop Process Monitoring Method for Quantitative
Analysis of Extended Drug Release Properties
6.1 Introduction
The capability of using analytical techniques such as NIR and Raman to determine pellet
coating thickness was successfully demonstrated in Chapter 5. By implementing the process
monitoring method of coating thickness, the hybrid control strategy was expected to be applicable
for pellet coating process with the purposes of core protection and drug release modification.
From the patient’s perspective, the rate at which the drug is released in vivo is clearly the
critical performance criterion. The development of in vitro in vivo correlations (IVIVC) involve
correlation between in vitro drug release profiles and pharmacokinetic data de-convoluted to show
the in vivo release profile (Level A). (FDA, 1997a). Besides its important role in IVIVC study, in
vitro drug release testing is a key evaluation in drug development and quality control (Nickerson
et al., 2009; Williams and Liu, 2000; Yuksel et al., 2000). It is employed to guide formulation
design and process optimization (Lorck et al., 1997b; Siepmann et al., 2008b).
However, the drug release test is time-consuming and requires many samples.(Freitas et
al., 2005) The destructive nature limits the product understanding when in need of a reexamination
of the sample for trouble-shooting. For a drug product developed using quality by design
approaches, the demand of conventional drug release test can be significantly reduced by
developing surrogate tests (FDA, 2004a, b). Spectroscopic methods are logical candidates to
substitute the in vitro drug release tests. In previous works, NIR and Raman methods demonstrated
their capability to allow quantitative analysis of the coating thickness. Because the drug release
properties of many coated products are affected by the coating thickness, it was hypothesized a
quantitative relationship exists between the drug release rate and the spectra.
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Therefore, the study of this chapter focused on developing empirical analytical models to
predict the drug release for a pellet coating process. Taking into account the proven advantages of
greater thickness range and superior model performance, the study in this chapter was investigated
using in-line NIR spectroscopy. The goals of this study were to: (1) establish empirical models
using NIR spectroscopy to determine the drug release profiles, and (2) assess the prediction
performance of the model. An extended release (ER) pellet dosage form was studied as a model
system for this work. Note this approach is specific to the investigated formulation system,
including coating and core materials, and therefore the study serves as a demonstration of the
modeling strategy.

6.2 Material and methods
6.2.1 Formulation of Extended Release Pellets
Extended release pellets were produced by applying a water-insoluble polymer dispersion
to the drug layered pellets prepared in chapter 4. Ethyl cellulose dispersion (Surelease type B NF,
Colorcon, PA), was applied to coat the drug layered pellets to achieve the desired ER drug release
properties. HPMC (PharmaCoat 606, Shin-Etsu, Japan) was added as a pore former to the polymer
dispersion, which was subsequently diluted by deionized water to the target solid concentration
shown in Table 6.1. Note, medium chain triglycerides and oleic acid were components contained
in the Surelease dispersion.
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Table 6. 1 Formulation of ethyl cellulose polymer dispersion

Polymer dispersion
Components
Ethyl cellulose
HPMC (606)
Medium chain triglycerides
Oleic acid
Deionized water

Concentration (w/w)
9.10%
0.60%
1.61%
1.05%
87.64%

6.2.2 Fluidized Bed Process, Sample Information, and Spectroscopic Data Collection
The coating process was operated using the Simplex control developed in chapter 2. The
EEF target was set 0.76. The details of the fluidized bed system, process measurements and NIR
setup are referred to Chapter 2 section 2.2. Six batches were produced in this work. Samples were
withdrawn from the process during the spraying phase, at a time interval corresponding to
approximately 4% weight gain change. A total of 28 samples were collected for calibration
(batches 1-5), and five samples for test (batch 6). The maximum range of the weight gain was
4.49-26.2 %.

6.2.3 Reference Method: In-vitro Drug Release Test
The drug release test was carried out using USP apparatus 1 (basket method).(USP) Six
replicates of each sample were tested. The rotational speed of the drive shaft was set at 50 rpm in
a dissolution apparatus (Dissolution system 2100B, DISTEK Inc., NJ). Deionized water was used
as the test medium, and the water bath temperature was controlled at 37 ± 0.5˚C. Aliquots of the
release medium were scanned every 15 min at 243 nm by a UV-Vis spectrometer (Agilent
Technologies, CA). The absorbance values were later converted to cumulative release percentages
using a UV-Vis calibration curve. All the measurements were normalized to the sample weights
(average of 2400 mg). The drug release profiles used for developing NIR models consisted of six
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measurements made at 1, 2, 3, 4, 6, and 8 hours. The desired drug release profiles were defined
using the USP monographs of Theophylline extended release capsules as a reference (USP).

6.2.4 NIR Drug Release Model Development
The NIR method development was similar to the protocols of empirical modeling described
in Chapter 3 section 3.2.4. A key distinction of this study lies in the reference values. The reference
values were drug release data determined by in-vitro drug release test. The release data were used
in two ways, raw data and release indices obtained by curve fitting. The NIR models were
established using two approaches. The model-independent NIR models were calculated by relating
spectra to the raw drug release data, whereas the model-dependent NIR models were built using
the release indices as reference values.

6.2.4.1

Model-independent Approach
The model-independent approach calculated the NIR models using two partial-least-

squares (PLS) regression algorithms: PLS-1 and PLS-2.
6.2.4.1.1 PLS-2 Algorithm
Due to its relative simplicity, PLS-2 algorithm was firstly used to build a NIR model.
Figure 6.1 (A) shows how the spectra is mathematically related to the reference values. X is a
matrix ([𝑛 × 𝑤]) containing the NIR spectra of 𝑛 samples scanned at 𝑤 wavelengths. Y is the
reference of drug release measurements, which consist of samples measured at multiple time points,
and therefore is a matrix with a dimension of [𝑛 × 𝑝]. The column size 𝑝 is the number of time
points of the drug release measurement. In this study, the drug release measurements were made
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at six time points and thus 𝑝 = 6. By correlating X and Y, a single PLS-2 model was calculated for
the whole group of samples at all the time points.
6.2.4.1.2

PLS-1 Algorithm

The models built using PLS-1 algorithm were more similar to the regular empirical models
described in chapter 3 (drug content) and chapter 5 (coating thickness). Figure 6.1 (B) shows the
reference data Y are multiple vectors, each with a dimension of [𝑛 × 1]. The number of the vectors
is equal to the time points of the drug release measurement. PLS algorithm was applied to each Y
vector separately, therefore a total of six PLS-1 models were calculated for the corresponding time
points.

Figure 6. 1 NIR calibration model development using model-independent approach. A: PLS-2; B: PLS-1.

6.2.4.2 Model-dependent approach
The model-dependent approach used the release indices as reference values. The release
indices were obtained by curve fitting the raw drug release data using various mathematical
equations. Each release index was an approximate indication of a drug release profile. The release
profiles were fitted using mathematical equations of first-order, Hixson-Crowell and Weibull as
follows,
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First-order:
Eq. (6.1)

= 1−𝑒
∞

Hixson-Crowell:
(1 −

)

/

Eq. (6.2)

=𝑘∙𝑡

∞

Weibull:
1−

= 1 − exp[

(

)

Eq. (6.3)

]

∞

where

is the cumulative release percentage at time t. The drug release indices of first-order and
∞

Hixson-Crowell are indicated by 𝑘, whereas the Weibull fitting has two indices of 𝛼 and 𝛽. NIR
spectra were related to the drug release indices to build PLS calibration models. In Figure 6.2, X1
is the NIR spectra of calibration, Y1 represents the reference drug release data, and k1 is the release
indices obtained by fitting Y1 using the equations described above. Notice, because two release
indices were calculated for Weibull fitting, therefore two Weibull models were generated.
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Figure 6. 2 NIR calibration model development using model-dependent approach.

Fitting errors were calculated for each mathematical equation used for curve fitting. The
steps are illustrated in Figure 6.3. The curve reconstruction was achieved by placing the estimated
drug release indices back to the same mathematical equation used for curve fitting, and to calculate
the reconstructed drug release profile, Yr. A RMSE was calculated between Y and Yr to indicate
the fitting performance of the equation used. The fitting error 𝑅𝑀𝑆𝐸

𝑅𝑀𝑆𝐸

=

∑

(

was expressed by,

, )

Eq. (6.4)

where 𝑝 is the total number of time points, 𝑌𝑡 is the reference measurement at a specific time point
𝑡, and 𝑌𝑟, 𝑡 is the reconstructed release percentages at the same time point.
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Figure 6. 3 Calculation of curve fitting error.

The procedures of predicting drug release using the developed NIR calibration models are
illustrated in Figure 6.4. X2 is the test spectra. The calibration model predicts the release indices
kp for the test. Predicted drug release profiles are subsequently calculated by curve reconstruction
using kp. The prediction error 𝑅𝑀𝑆𝐸

𝑅𝑀𝑆𝐸

=

∑

(

,

is calculated by,

, )

Eq. (6.5)

Here 𝑌2, 𝑡 is the reference measurement of the test at time t.
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Figure 6. 4 Illustration of the predictions provided by NIR models built using model-dependent approach.

6.2.5 Model Performance Assessment
Unlike a normal evaluation of the NIR model performance by comparing the prediction
error to the reference error, there is no well-accepted standard to guide the assessment of the NIR
model prediction of drug release profiles. Therefore, two methods were used in this work from
different standpoints. The first approach was similarity factor (f2) used by regulatory agency to
examine product’s bioequivalence. The second approach was mahalanobis distance (MD), which
is often used to measure the difference between two multivariate data set.

6.2.5.1 Similarity Factor (f2)
Similarity test, f2, is a mathematical index (0 <= f2 <= 100) often used to measure the
difference between the drug release of test and reference formulations. The index was constructed
by a function of Euclidean distance between two drug release vectors. Notice that f2 of 100 implies
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the two release profiles are identical, whereas f2 of 0 indicates the two profiles are completely
different: the release of one formulation is completed before the other begins. An average
difference of 10% at all time points would give an f2 close to 50. A f2 >= 50 is considered similar
in terms of bioequivalence (FDA, 1997b, 2014). Therefore, f2 was used as a method premised on
regulatory perspective to assess the difference between NIR prediction and reference. It is
calculated by,
𝑓2 = 50 ∙ log(

Eq. (6.6)

∙ 100)
∙∑

(

)

where 𝑓2 is an unweighted RMSE over the whole drug release profile with a total 𝑝 time points,
𝑌1 and 𝑌2 are the release percentages of reference measurements and predictions at a time
point 𝑡.

6.2.5.2 Mahalanobis Distance (MD)
Drug release profiles measured at multiple time points are essentially a multivariate data
set. The data are highly correlated because the release percentage at each time point is related with
all other time points. Therefore, classic Euclidean distance may not be the most appropriate method
to assess the difference between two release profiles. MD is a statistical distance often used to
measure the difference between two multivariate means. The MD is expressed as,

MD =

(𝑌 − 𝑌 )′ ∙ 𝑆

Eq. (6.7)

∙ (𝑌 − 𝑌 )

where 𝑌 and 𝑌 represent the reference and prediction of the release profiles, respectively. 𝑆
is the inverse of the sample variance-covariance matrix pooled from the prediction and
measurement (Tsong et al., 1996).
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To acquire MD measurements with statistical evidence and reduce the probability of
making type I error, error propagation was used to take into account various types of uncertainty
related to the predictions. The sources of the uncertainty were drug release test, sampling, NIR
data collection, fitting and modeling errors, etc. The variance of the drug release measurements
were used to indicate the uncertainty of the drug release test and sampling, which was calculated
from the release data of sample replicates at different coating weight gain. The uncertainty of NIR
data was from the sample under interrogation, NIR spectrometer, and common cause process
variance. The uncertainties were nested in the individual NIR spectra collected in real time.
Therefore, instead of using the average, the individual in-line NIR spectra were used to calculate
the prediction of drug release. The uncertainty of the modeling indicated by the drug release fitting
error and modeling error. The curve fitting error 𝑅𝑀𝑆𝐸

and overall prediction error 𝑅𝑀𝑆𝐸

were calculated using Eq. (4) and (5), respectively. The variances of the described sources were
pooled together, and translated to the predictions via error propagation.

6.3

Results and Discussion

6.3.1 NIR Drug Release Model
6.3.1.1 Model-independent Approach
The first NIR model was developed using PLS-2 algorithm. The predictions of drug release
provided by PLS-2 are overlaid with reference measurements and are shown in Figure 6.5 (A).
The samples coated at different weight gains are indicated by colors. The solid points are reference
measurements, and the open circles are predictions. Each sample had considerably high prediction
error. The PLS-1 approach considerably improved the prediction error, as evidenced by the data
shown in Figure 6.5 (B). The PLS-1 models were established by preprocessing the spectra using
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SNV and mean-centering, and including two latent variables. The difference in the model
performance was inferred associated with how the Y was used in the calculation. In PLS-2
algorithm, Y was a multivariate and highly correlated data set. Because the release percentage of
each time were strongly related to adjacent time points, an irrelevant variance contained at one
time point inherently propagated to the next time point. The more irrelevant Y-variance caused a
co-variance captured by the PLS-2 model.

Figure 6. 5 Predictions of drug release profiles provided by NIR models built using model-independent approach. A:
PLS-2 predictions (open circles) and reference measurements (solid circles); B: PLS-1 predictions (open circles
dashed lines) and reference measurements (solid circles lines).

6.3.1.2 Model-dependent approach
The raw drug release data were fitted using different mathematical equations described in
6.2.3.2. The results are listed in Table 6.2. The release indices of first-order and Hixson-Crowell
fittings are represented by k and hck, respectively. The two indices of Weibull fitting are
indicated by α and β. The fitting errors for each mathematical equations are also shown in the
Table. Note, batches 1-5 were calibration batches, and batch 6 was the test batch.
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Table 6. 2 Estimated release indices and fitting errors of first-order, Hixson-Crowell, and Weibull equations.

Batch
#
1

2

3

4

5

6

Sample #
1
2
3
4
5
1
2
3
4
5
6
1
2
3
4
5
1
2
3
4
5
6
1
2
3
4
5
6
1
2
3
4
5

Release indices by curve fitting
FirstHixsonWeibull
order
Crowell
k
hck
α
β
2.1
0.49
0.51
1.30
0.53
0.17
2.16
1.28
0.33
0.08
5.08
1.28
0.20
0.05
7.24
1.15
0.11
0.03
11.42
1.08
3.48
0.78
0.27
1.21
0.89
0.22
1.50
1.29
0.20
0.05
5.19
1.04
0.20
0.05
6.88
1.15
0.17
0.05
8.13
1.12
0.14
0.04
9.07
1.07
1.01
0.25
1.24
1.28
0.31
0.07
4.78
1.19
0.24
0.06
6.46
1.18
0.15
0.04
9.99
1.20
0.12
0.03
11.41
1.10
0.73
0.18
2.00
1.30
0.43
0.10
3.70
1.27
0.31
0.08
5.13
1.23
0.25
0.06
7.10
1.26
0.18
0.05
9.19
1.22
0.15
0.04
10.82
1.20
0.55
0.14
2.52
1.19
0.33
0.08
4.08
1.17
0.24
0.06
5.54
1.18
0.23
0.05
5.80
1.09
0.14
0.04
8.05
1.17
0.12
0.03
7.86
1.10
0.72
0.18
1.99
1.27
0.46
0.12
2.67
1.31
0.35
0.09
4.11
1.21
0.23
0.06
5.55
1.17
0.17
0.05
11.37
1.23

Fitting errors (𝑅𝑀𝑆𝐸 )
First-order

HixsonCrowell

Weibull

19.02%
5.17%
7.25%
5.59%
3.07%
4.94%
8.81%
3.26%
4.26%
4.21%
3.04%
3.38%
2.48%
2.61%
2.34%
2.62%
9.63%
7.77%
6.35%
6.90%
5.55%
5.45%
7.78%
5.31%
4.49%
6.58%
6.09%
7.95%
8.99%
7.04%
6.26%
4.34%
5.98%

13.88%
4.76%
2.96%
2.42%
1.68%
2.07%
4.42%
7.01%
2.21%
1.56%
1.62%
3.38%
2.48%
2.61%
2.34%
2.62%
5.49%
3.46%
7.30%
3.20%
2.94%
3.52%
3.03%
2.57%
3.93%
4.71%
6.42%
8.99%
4.14%
6.86%
2.44%
3.71%
5.85%

2.94%
1.50%
1.15%
1.52%
1.20%
0.23%
1.18%
2.83%
1.74%
1.12%
1.24%
1.04%
1.25%
1.48%
0.79%
1.33%
1.92%
1.38%
1.58%
1.25%
1.07%
1.02%
1.52%
2.03%
1.95%
2.83%
2.31%
2.46%
1.62%
3.26%
1.77%
2.05%
3.01%

The NIR models calculated using first-order, Hixson-Crowell, and Weibull fittings were
called first-order model, Hixson-Crowell model, and Weibull model for short in the results and
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discussion. The optimized models of first-order and Hixson-Crowell were developed by
preprocessing the spectra using SNV followed by mean-centering, and the Weibull model was
optimized using preprocessing of first derivative and mean-centering. All the models were
calculated using three latent variables. The predictions of release indices versus the reference
values obtained by curve fitting are shown in Figure 6.6: first-order (A), Hixon-Crowell (B), and
Weibull (C). Note, the β index of Weibull fitting was not used to build the model. The β index
obtained by curve fitting had a very limited range of 1.04 – 1.30. Also, the changes in the drug
release profiles were dominated by the change in scale (α) instead of shape (β). Therefore the index
β was kept at a constant average value of 1.20. The predicted release profiles were reconstructed
using the predicted release indices. The comparisons of predicted drug release by the modeldependent approach with the reference measurements are shown in Figure 6.7.

Figure 6. 6 Predicted versus curve fitted release indices. A: First-order, B: Hixson-Crowell, and C: α index of Weibull.
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Figure 6. 7 Prediction of drug release profiles provided by NIR model built using model-independent approach. A:
First-order; B: Hixson-Crowell; and C: Weibull.

6.3.2 Assessment of Model Performance
6.3.2.1 Similarity Factor (f2)
Similarity factor values were calculated for the test samples with different coating weight
gain. Figure 6.8 reveals the f2 values of most of the models are above 50 with the exception of
PLS-2 model which has f2 values all below 50. For the other models with f2 greater than 50, they
were considered “similar” to the reference measurements at a criteria based on regulatory
perspective. The criteria was originally defined to assess the sameness between two products made
of different formulation or manufactured at different times (Ma et al., 2000). From a perspective
of bioequivalence, f2 is a reasonable method to compare two products. A stricter criterion may
jeopardize drug product’s affordability and availability.
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Figure 6. 8 F2 values of the predictions provided by all of the NIR models. Red line: f2 = 50.

Nevertheless, the goal of a NIR model is to provide predictions as close as possible to the
reference measurements. Therefore, f2 assessment is not the most appropriate way to assess the
prediction performance. A simulation study was performed to illustrate this drawback. In Figure
6.9 (A), the green lines are in-vitro drug release measurements, the red area is composed of
numerous simulated drug release profiles that have f2 >= 50 (compared to the average of the
measurements), and the blue dashed lines are the boundaries indicating f2 = 50. A PCA calibration
model was built using the drug release data of the measurements to test the simulated drug release
profiles. The PCA scores are shown in Figure 6.9 (B). Most of the simulations (red diamonds) are
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on the outside of the confidence interval defined by the reference measurements (dashed circle).
The results indicated the criteria of f2 >= 50 is not premised on statistical inference.

Figure 6. 9 Illustration of f2 criteria by simulation. A: Simulated drug release profiles with f2 >= 50; B: PCA
calibration model (reference measurements) and test (simulated drug release).

6.3.2.2 Mahalanobis Distance
The effects of uncertainties, from various sources, on the predictions of drug release were
studied by error propagation. Figure 6.10 (A) shows the reference measurements. The observed
variation was mainly associated with the uncertainty of drug release test and samples. The error
propagated drug release profiles predicted by first-order, Hixson-Crowell, and Weibull models are
shown in Figure 6.10 (B) – (D), respectively. Although all the predictions had much greater
variances than the reference measurements, the ones of the Hixson-Crowell model were
considerably lower than the other models. Since all the models had similar uncertainty of drug
release tests, sampling and NIR data collection, the lower variations observed in the HixsonCrowell model were attributed to its lower overall prediction error. The prediction error consisted
of errors from modeling and curve fitting. The two types of errors were convoluted because of the
curve reconstruction. By taking into account the fitting error (calculated and shown in Table 6.2),
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the de-convoluted errors are shown in Figure 6.11. Note, in the figure, the errors refer to mean
squared error (MSE). The red bars indicate the fitting errors of each equation, whereas the green
bars represent the modeling error, which was obtained by subtracting the fitting error from the
overall prediction error.
The first-order model had reasonable modeling error, indicating there was valid
correlation between the coatings of the ER pellets with the NIR spectra. This was supported by
the studies in chapter 5, where empirical NIR models were developed and were able to predict
the pellet coating thickness. However, the first-order model had very poor fitting to the drug
release profiles, indicating the drug release of the ER pellets was not primarily controlled by
diffusion mechanism (which is expected to be fitted well by first-order kinetics). The Weibull
model gave much better fitting results than first-order and Hixson-Crowell models, however it
did not provide the most accurate predictions. Extremely high prediction errors were observed
for sample 2 and 4, which were due to their high modeling errors when predicting the α index
(the prediction errors of samples 2 and 4 were 8.6 and 10.8 times larger than sample 3). The
reasons for the higher prediction errors were unclear due to Weibull’s lack of physical
connection with the drug release mechanism, and inferred mainly associated with the
mathematical computation of PLS model (possible interactions among the α index and the
uncertainty of samples).
In general, the Hixson-Crowell model gave lower prediction errors. It had reasonably low
fitting errors as evidenced by the data shown in Figure 6.11. A conjectured drug release
mechanism is illustrated in Figure 6.12. The structure of ER pellet before subjecting to the drug
release test is shown in Figure 6.12 (A). As the drug release test started, the release medium
gradually diffused through the EC film to the drug layer. The drug layer, which had water
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soluble drug dispersed in a hydrophilic polymer HPMC matrix, hydrated when it was in contact
with water, as depicted in Figure 6.12 (B). At the initial stage, the drug release followed a zeroorder model, which was supported by an average R 2 of 0.999 for release percentage below 30%.
Literature reports hydrated HPMC forms a viscous gel layer, acting as a barrier to drug diffusion
by opposing penetration of water (Wen and Park, 2010). Therefore, excess of drug may be
present to maintain saturation on the surface of the hydrated gel layer, and the drug release rate
was mainly controlled by diffusion from non-disintegrating matrix. Although the EC film is
water-insoluble, it was presumed had decreasing impact on the overall drug release as the release
test continued. Besides the pathways within the EC film created by water-soluble pore former
(HPMC), the swelling nature of the drug layer exerted pressure on the EC film and may resulted
in film breakage. This was supported by the fact that holes were visualized on the surface of EC
film after the drug release test. The breakage of the EC film significantly lessened its importance
of regulating the drug diffusion through the membrane. Besides the drug layer’s swellable
property, it was also erodible and dissolvable, and therefore the volume and surface area of the
drug layered pellet beneath the EC film gradually diminished. This possible process is shown in
Figure 6.12 from (C) to (D). Consequently, the drug release of ER pellets was considered
regulated by a combination of diffusion, swelling/erosion, and geometry/area changes (Wen and
Park, 2010). Owing to its spherical shape, this might explain why the drug release profiles can be
fitted better by Hixson-Crowell model. It should be noted that Hixson-Crowell model assumed a
constant concentration gradient is maintained during the drug release (Frenning et al., 2003;
Hixson and Crowel, 1931), which was not the case in practice. The gradually decreased
concentration gradient lead to further reduced rate constant in addition to the effect of the
diminished surface area. This might explained its greater fitting errors than the Weibull model.
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Because of the lower fitting errors and the correlation between NIR spectra and the pellet coating
thickness, the Hixson-Crowell model gave an acceptable overall prediction performance, which
was superior to the first-order and Weibull models. Since the objective of this study was to build
an empirical drug release model using NIR, the in-depth investigation of the drug release
mechanism was considered as a future direction which should be pursued in future studies.

Figure 6. 10 Drug release profiles calculated by error propagation. A: Reference measurements; B: Predictions of the
first-order model; C: Predictions of the Hixson-Crowell model; D: Predictions of the Weibull model.
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Figure 6. 11 Comparison of the overall prediction error, fitting error, and modeling error of the NIR models built using
model-dependent approach.

Figure 6. 122 Schematic illustration of the possible drug release mechanism of the ER pellets.

142

The MDs of the predicted drug release profiles were calculated and the average values are
listed in Table 6.3. The last column in the table shows the MDs of reference measurements,
indicating the multivariate distances of each individual drug release profile to the average release
profile. The MD of reference measurements reflected the inherent uncertainty in sampling and
drug release test, therefore was perceived as the reference error.
Table 6. 3 Mean mahalanobis distances between the predictions and reference measurements.

Sample #
1
2
3
4
5
Mean

Mean mahalanobis distance between predictions and measurements
First-order
Hixson-Crowell
Weibull
Reference Measurement
7.37
5.48
1.55
1.57
8.17
4.13
11.14
1.53
5.77
2.62
1.43
1.23
6.50
2.73
5.83
1.28
27.25
14.35
37.89
1.22
12.74
6.15
20.99
1.33

The Hixson-Crowell model outperformed first-order and Weibull models. Tukey all
pairwise test was used to make statistical comparisons between the predictions and measurements
for all of the three models. The results are shown in Table 6.4. The symbols of “**” and “*”
indicate a statistical difference at significant level of 0.001 and 0.05, respectively. The predictions
of sample 2, 3, and 4 provided by the Hixson-Crowell model were statistically indistinguishable
from the reference measurements. Figure 6.12 shows the desired drug release profile (using USP
monographs of Theophylline as a guide) is in the middle of sample 3 and 4. Therefore, the HixsonCrowell model was considered having a superior prediction performance for the investigated ER
pellet sample.
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Table 6. 4 Tukey all pairwise comparison of the mahalanobis distances between predictions and reference
measurements. **: P < 0.001; *: P < 0.05.

Sample #
1
2
3
4
5

First-order
**
**
**
**
**

Hixson-Crowell
**

Weibull
**

*

Figure 6. 13 Predictions of Hixson-Crowell model versus desired drug release profile.
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**
**

6.4 Conclusion
An empirical NIR model was successfully developed to determine the drug release profiles
of ER pellets. Different approaches were used to build the drug release model. The prediction
performances of NIR models were assessed using f2 and MD. The f2 were all greater than 50
except the one calculated by PLS-2 algorithm. F2 provides important criteria from the regulatory
perspectives. However, the simulation study proved the criteria of f2 = 50 was not based on
statistical inference.
MD was used to establish a stricter criteria based on statistical inference. The variations
from several sources associated with the NIR predictions were estimated. The effects of the
variations on prediction performance was probed by error propagation. The MDs of reference
measurements were calculated and used as the reference error. The MDs between the NIR
predictions and reference measurements were compared with the reference error. Tukey all
pairwise test was employed to deduce the statistical conclusion. Given the desired drug release
profile defined by USP monographs, the NIR model developed using Hixson-Crowell equation
was perceived the optimized model.
The drug release profiles of an ER pellet dosage form were adequately predicted in the
desired range. The stricter criteria defined by MD were advantageous to ensure the reliability of
the predictions, allowing it to be used as a process monitoring method implemented in the proposed
hybrid control system. The successful development of the NIR method holds promise to reduce
the use of destructive and time-consuming drug release tests, allow real time quality assurance,
and support a process to achieve real time release.
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Chapter 7 Summary
To date, most pharmaceutical batch processes are still operated under the basic control.
The basic control has several drawbacks. To avoid additional regulatory submission, the process
settings discovered by trial and errors are often held constant. The rigid process operation limits
the opportunities for improved process understanding and optimization. Because in-line analyzers
are often unavailable, the product quality is usually tested off-line using end product tests. The
quality attributes measured in this way cannot be used in feedback to make efficient process
adjustment and allow continuous process improvement. As a result, the product quality is trapped
in the batch process endpoint. The uncertainty in end product quality requires frequent
reprocessing and may lead to more batch failures. Consequently, the basic control does not
effectively ensure the product quality and hence has limited the process capability.
The pharmaceutical industry has been seeking solutions to address the issues mentioned
above. Alternative process control strategy is seemingly a logical way to improve the process
capability. Unlike another promising solution using continuous process, the development of
alternative process control does not require expensive capital investment for building the
infrastructures. Given the greater adaptability of batch processes, the alternative control approach
is expected to have broader applications. A hybrid process control system was proposed in the
dissertation as an example to illustrate the alternative control strategy. The goals of the hybrid
control were to ensure product quality and improve process capability. A challenging unit
operation, fluidized bed pellet coating process, was investigated as a model system to develop and
demonstrate the control system.
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The hybrid control system consisted of three elements: process manipulation, monitoring,
and optimization. A process manipulation strategy was developed in chapter 2 with the goal of
achieving successful process operations. The manipulation was premised on the first principle
understanding of the coating process. Environmental equivalency factor (EEF) was used to
regulate the drying environment, which was executed using the Simplex control algorithm. The
Simplex control was able to maintain the EEF at its target by simultaneously changing three
manipulated parameters. The same EEF produced a consistent drying environment during the
coating process, which was supported by the NIR PCA results. The batch failures frequently
encountered under the basic control was successfully eliminated by using the first principle control.
Several process monitoring systems were developed using various spectroscopic methods.
Real time quantitative analyses of CQAs were enabled by building empirical models using in-line
NIR and Raman spectroscopy. The process endpoint automatically ended when the desired quality
limits were met, which was demonstrated in the drug layering study. In chapter 5, the capabilities
of quantitative determination of pellet coating thickness were investigated using NIR, Raman, and
Terahertz imaging. Each technique had unique strengths, and were all considered valuable tools
due to their complementary characteristics. In chapter 6, an empirical NIR model was built to
predict the drug release profiles of an ER pellet dosage form. Given the desired drug release range,
the model-dependent approach using Hixson-Crowell was able to provide adequate predictions.
The predicted drug release profiles were statistically indistinguishable from the corresponding
reference measurements.
An operational space was established for a drug layering process in chapter 4 to achieve
process optimization. A design space was developed ahead of time using design of experiments.
The investigated process factors were the EEF and atomization pressure. The results indicated both
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factors had significant influences on the quality attributes of interest, including coating efficiency,
content uniformity, and agglomeration percentage. Edge of failure analysis was performed by
taking into account the individual variability of each process factor. This allowed to calculate the
probabilities of in specifications for each setpoint in the design space. The operation space was
discovered in the design space based on a specified requirement of confidence level. The optimized
process was endowed with greater confidence to meet the specifications.
The hybrid control system substantially improved the process capability for the drug
layering process compared to the basic control. The results were supported by the statistically
increased process capability indices. The works in this dissertation served to illustrate the
capability of the alternative process control strategy. The control elements are adaptable and can
be altered to suit the specific needs of a process. The successful demonstration of the alternative
control strategy offers encouraging opportunities to improve the process capability for
pharmaceutical manufacturing using batch processing.
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